{
    "children": [
        {
            "name": "Antibody",
            "color": "green",
            "children": [
                {
                    "name": "Sequence",
                    "color": "green",
                    "children": [
                        {
                            "name": "Variable Region",
                            "color": "green",
                            "children": [
                                {
                                    "name": "CDRs",
                                    "color": "green",
                                    "claimReason": "“... with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 ...”",
                                    "indClaim": "<p>[IC]</p>12. An isolated human antibody, or an antigen-binding portion thereof, with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8, and with a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11.",
                                    "depClaim": "<p>[DC]</p>13. The isolated human antibody, or an antigen-binding portion thereof, of claim 12, wherein the LCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 and the HCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6. <p>[DC]</p>14. The isolated human antibody, or an antigen-binding portion thereof, of claim 13, wherein the LCVR further has CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 and the HCVR has a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",
                                    "source": "<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                                },
                                {
                                    "name": "Framework Region",
                                    "color": "green",
                                    "claimReason": "“… comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of 73H, 78H, 93H and 66L …”",
                                    "indClaim": "<p>[IC]</p> 20. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and; <p>(a)</p> binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity; and <p>(b)</p> comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of 73H, 78H, 93H and 66L, utilizing the numbering system set forth in Kabat.",
                                    "depClaim": "<p>[DC]</p> 21. The humanized variant of claim 20 which consists of about 1 to about 5 FR substitutions.<p>[DC]</p> 22. The humanized variant of claim 20 which comprises a FR substitution at site 73H.<p>[DC]</p> 23. The humanized variant of claim 20 which comprises a FR substitution at site 78H.<p>[DC]</p> 24. The humanized variant of claim 20 which comprises a FR substitution at site 93H.<p>[DC]</p> 25. The humanized variant of claim 20 which comprises a FR substitution at site 66L.<p>[DC]</p> 26. The humanized variant of claim 20 which further comprises a FR substitution at site 71H.<p>[DC]</p> 27. The humanized variant of claim 26 which comprises FR substitutions at sites 71H, 73H, 78H, 93H and 66L.",
                                    "source": "<p>Source:</p> US6054297A, Genentech Company: Avastin® Product"
                                }
                            ]
                        },
                        {
                            "name": "Full Length",
                            "color": "green",
                            "claimReason": "“… comprising a heavy chain comprising ... and a light chain comprising …”",
                            "indClaim": "<p>[IC]</p> 11. An isolated antibody comprising a heavy chain comprising amino acid residues 20 to 446 of SEQ ID NO: 31 and a light chain comprising amino acid residues of 20-237 of SEQ ID NO: 36.",
                            "depClaim": "<p>[DC]</p> None",
                            "source": "<p>Source:</p> US8354509B2, Merck & Co Company: Keytruda® Product"
                        },
                        {
                            "name": "Nano Bodies",
                            "color": "green"
                        },
                        {
                            "name": "Constant Region",
                            "color": "green",
                            "claimReason": "“... an IgG1 heavy chain constant ...”",
                            "indClaim": "<p>[IC]</p> 15. An isolated human antibody, or an antigen binding portion thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",
                            "depClaim": "<p>[DC]</p> 16. The isolated human antibody of claim 15, which has an IgG1 heavy chain constant region.<p>[DC]</p> 17. The isolated human antibody of claim 15, which has an IgG4 heavy chain constant region.<p>[DC]</p> 18. The isolated human antibody of claim 15, which is a Fab fragment.<p>[DC]</p> 19. The isolated human antibody of claim 15, which is a single chain Fv fragment.",
                            "source": "<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                        }
                    ]
                },
                {
                    "name": "Bi-Specific",
                    "color": "green",
                    "children": [
                        {
                            "name": "Normal",
                            "color": "green"
                        },
                        {
                            "name": "Single Chain",
                            "color": "green",
                            "claimReason": "“… single-chain multi-functional polypeptide comprising …”",
                            "indClaim": "<p>[IC]</p> 1. A single-chain multi-functional polypeptide comprising: <p>(a)</p> a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD19 antigen. <p>(b)</p> a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V L CD19-VHCD19-VHCD3-VLCD3.",
                            "depClaim": "<p>[DC]</p> 2. The polypeptide of claim 1, wherein said two domains are connected by a polypeptide linker.<p>[DC]</p> 3. The polypeptide of claim 1, wherein said first and/or second domain correspond to a VH and VL region from a natural antibody.<p>[DC]</p> 4. The polypeptide of claim 1, wherein said antibody is monoclonal antibody, synthetic antibody, or humanized antibody.<p>[DC]</p> 5. The polypeptide of claim 4, wherein at least one of said domains is a single-chain fragment of the variable region of the antibody.<p>[DC]</p> 6. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of glycine, alanine, serine residues or combinations thereof.<p>[DC]</p> 7. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of consecutive copies of an amino acid sequence.<p>[DC]</p> 8. The polypeptide of claim 2, wherein said polypeptide linker comprises 1 to 5 amino acid residues.<p>[DC]</p> 9. The polypeptide of claim 8, wherein said polypeptide linker comprises the amino acid sequence Gly Gly Gly Gly Ser.<p>[DC]</p> 10. The polypeptide of claim 1, wherein <p>(a)</p> said binding site of the first domain has an affinity of at least about 10 -7 M; and/or<p>(b)</p> said binding site of the second domain has an affinity of less than about 10 -7 M.<p>[DC]</p> 11. The polypeptide of claim 1, wherein said polypeptide is a bispecific single-chain antibody.<p>[DC]</p> 12. The polypeptide of claim 1, comprising at least one further domain.<p>[DC]</p> 13. A The polypeptide of claim 12, wherein said further domain is linked by covalent or noncovalent bonds.<p>[DC]</p> 14. The polypeptide of claim 12, wherein said at least one further domain comprises an effector molecule having a conformation suitable for biological activity, capable of sequestering an ion or selective binding to a solid support or to a preselected determinant.<p>[DC]</p> 15. A method for the preparation of a single-chain multi-functional polypeptide comprising: cultivating a cell transfected with a polynucleotide which upon expression encodes the singlechain multi-functional polypeptide of claim 1; and isolating said polypeptide from the cell.",
                            "source": "<p>Source:</p> US7112324B1, Amgen Company: Blincyto® Product"
                        }
                    ]
                },
                {
                    "name": "Function",
                    "color": "green",
                    "children": [
                        {
                            "name": "Affinity",
                            "color": "green",
                            "claimReason": "“… dissociates from human TNF with a Kd of 1×10-8 M or less and a Koff rate constant of 1×10-3 s-1 or less …”",
                            "indClaim": "<p>[IC]</p> 1. An isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF with a Kd of 1×10-8 M or less and a Koff rate constant of 1×10-3 s-1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-7 M or less.",
                            "depClaim": "<p>[DC]</p> 2. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which dissociates from human TNF with a Koff rate constant of 5×10-4 s-1 or less.<p>[DC]</p> 3. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which dissociates from human TNF with a Koff rate constant of 1×10-4 s-1 or less.<p>[DC]</p> 4. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-8 M or less.<p>[DC]</p> 5. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-9 M or less.<p>[DC]</p> 6. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-10 M or less.<p>[DC]</p> 7. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which is a recombinant antibody, or antigen-binding portion thereof.<p>[DC]</p> 8. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which inhibits human TNF-induced expression of ELAM-1 on human umbilical vein endothelial cells.",
                            "source": "<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Cytotoxicity",
                            "color": "green",
                            "claimReason": "“… and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less …”",
                            "indClaim": "<p>[IC]</p> 54. A pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less, and a pharmaceutically acceptable carrier, wherein the composition has a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppository.",
                            "depClaim": "<p>[DC]</p> None",
                            "source": "<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Binding Inhibition",
                            "color": "green",
                            "claimReason": "“… interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR) …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein the heavy chain and light chain form an antibody that interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein: <p>a)</p> the heavy chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 13; and <p>b)</p> the light chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 14.<p>[DC]</p> 3. The method of claim 2, wherein the heavy chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 13 and the light chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 14.",
                            "source": "<p>Source:</p> US8409578B2, Amgen Company: Prolia® Product"
                        },
                        {
                            "name": "Epitope",
                            "color": "green",
                            "claimReason": "“… antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence …”",
                            "indClaim": "<p>[IC]</p> 1. A method for the treatment of a human patient with a malignant progressing tumor or cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an intact antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence and a taxoid, in the absence of an anthracycline derivative, to the human patient in an amount effective to extend the time to disease progression in said human patient, without increase in overall severe adverse events.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1 wherein said patient has a malignant tumor.<p>[DC]</p> 3. The method of claim 1 wherein said patient has cancer.<p>[DC]</p> 4. The method of claim 3 wherein said cancer is selected from the group consisting of breast cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.<p>[DC]</p> 5. The method of claim 4 wherein said cancer is breast cancer.<p>[DC]</p> 6. The method of claim 5 wherein said cancer is metastatic breast carcinoma.<p>[DC]</p> 7. The method of claim 1 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.<p>[DC]</p> 8. The method of claim 1 wherein said taxoid is paclitaxel.<p>[DC]</p> 9. The method of claim 8 wherein the effective amount of said combination is lower than the sum of the effective amounts of said anti-ErbB2 antibody and said taxoid, when administered individually, as single agents.<p>[DC]</p> 10. The method of claim 1 wherein efficacy is further measured by determining the response rate.",
                            "source": "<p>Source:</p> US7846441B1, Genentech Company: Herceptin® Product"
                        }
                    ]
                },
                {
                    "name": "Properties",
                    "color": "green",
                    "children": [
                        {
                            "name": "HPLC Properties",
                            "color": "green",
                            "claimReason": "“… wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab …”",
                            "indClaim": "<p>[IC]</p> 1. A composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",
                            "depClaim": "<p>[DC]</p> 2. The composition of claim 1, wherein the acidic species of adalimumab comprise a first acidic region (AR1) and a second acidic region (AR2).<p>[DC]</p> 3. The composition of claim 1, wherein the composition comprises less than 3.8% total acidic species of adalimumab.<p>[DC]</p> 4. The composition of claim 2, wherein the composition comprises 0.8% AR1 and 3.0% AR2.<p>[DC]</p> 5. The composition of claim 1, wherein the composition comprises less than 2.4% total acidic species of adalimumab.<p>[DC]</p> 6. The composition of claim 2, wherein the composition comprises 0.2% AR1 and 2.2% AR2.<p>[DC]</p> 7. The composition of claim 1, wherein the composition comprises 4.7%-8.3% total acidic species of adalimumab.<p>[DC]</p> 8. The composition of claim 7, wherein the composition comprises 4.7% total acidic species of adalimumab.<p>[DC]</p> 9. The composition of claim 7, wherein the composition comprises 5.0% total acidic species of adalimumab.<p>[DC]</p> 10. The composition of claim 7, wherein the composition comprises 5.8% total acidic species of adalimumab.<p>[DC]</p> 11. The composition of claim 7, wherein the composition comprises 6.1% total acidic species of adalimumab.<p>[DC]</p> 12. The composition of claim 7, wherein the composition comprises 6.4% total acidic species of adalimumab.<p>[DC]</p> 13. The composition of claim 7, wherein the composition comprises 8.1% total acidic species of adalimumab.<p>[DC]</p> 14. The composition of claim 7, wherein the composition comprises 8.3% total acidic species of adalimumab.<p>[DC]</p> 15. The composition of claim 2, wherein the composition comprises 0.8%-1.4% AR1.<p>[DC]</p> 16. The composition of claim 2, wherein the composition comprises 3%-9% AR2.17. The composition of claim 2, wherein the composition comprises 0.8% AR1 and 6.4% AR2.<p>[DC]</p> 18. The composition of claim 2, wherein the composition comprises 0.9% AR1 and 9% AR2.<p>[DC]</p> 19. The composition of claim 2, wherein the composition comprises 1.2% AR1 and 7.7% AR2.<p>[DC]</p> 20. The composition of claim 2, wherein the composition comprises 1.2% AR1 and 8.2% AR2.<p>[DC]</p> 21. The composition of claim 2, wherein the composition comprises 1.4% AR1 and 8.4% AR2.<p>[DC]</p> 22. The composition of claim 2, wherein the composition comprises 1.4% AR1 and 8.6% AR2.<p>[DC]</p> 23. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.",
                            "source": "<p>Source:</p> US9334319B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Residue",
                            "color": "green",
                            "claimReason": "“… lysine variant species …”",
                            "indClaim": "<p>[IC]</p> 7. A composition comprising a human anti-TNF antibody, wherein the sum of the lysine variant species having one C-terminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 35%, wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, and wherein the human anti-TNF antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4.",
                            "depClaim": "<p>[DC]</p> 8. The composition of claim 7, wherein said human anti-TNF antibody is adalimumab.<p>[DC]</p> 9. The composition of claim 8, wherein the sum of the lysine variant species having one C-terminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 40%.<p>[DC]</p> 10. The composition of claim 8, wherein the sum of the lysine variant species having one Cterminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is 40-50%.<p>[DC]</p> 11. The composition of claim 8, wherein the sum of the lysine variant species having one Cterminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 50%.<p>[DC]</p> 12. The composition of claim 8, wherein greater than 25% of the lysine variant species in said composition have one C-terminal lysine (Lys 1).<p>[DC]</p> 13. The composition of claim 8, wherein greater than 30% of the lysine variant species in said composition have one C-terminal lysine (Lys 1).<p>[DC]</p> 14. The composition of claim 7, wherein said composition is lyophilized.<p>[DC]</p> 15. A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier.<p>[DC]</p> 16. A pharmaceutical formulation comprising the composition of claim 7 and a pharmaceutically acceptable carrier.",
                            "source": "<p>Source:</p> US9181337B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Other",
                            "color": "green",
                            "claimReason": "“… mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human …”",
                            "indClaim": "<p>[IC]</p> 15. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and: <p>(a)</p> binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity: <p>(b)</p> mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human peripheral blood lymphocytes at least about four fold more effectively than the non-human parent antibody; and <p>(c)</p> mediates Antibody Dependent Cellular Cytotoxicity (ADCC) selective for cell types which overexpress p185HER2 at least about two fold more effectively than for cell types which express low levels of p185HER2.",
                            "depClaim": "<p>[DC]</p> 16. The humanized variant of claim 15 which binds the HER2 receptor with an affinity of about 0.82 nM Kd or better affinity.<p>[DC]</p> 17. The humanized variant of claim 16 which binds the HER2 receptor with an affinity of about 0.10 nM Kd.<p>[DC]</p> 18. The humanized variant of claim 15 which inhibits proliferation of SK-BR-3 cells incubated for 96 hr with the antibody.<p>[DC]</p> 19. The humanized variant of claim 18 wherein the antibody inhibits proliferation of SK-BR-3 cells to about 66% of untreated control or greater inhibition.",
                            "source": "<p>Source:</p> US6054297A, Genentech Company: Avastin® Product"
                        }
                    ]
                },
                {
                    "name": "Modified Antibody",
                    "color": "green",
                    "claimReason": "“… the main species HER2 antibody comprising an amino-terminal leader extension …”",
                    "indClaim": "<p>[IC]</p> 1. A composition comprising: <p>(a)</p> a main species HER2 antibody that binds to domain II of HER2 and comprises the variable light amino acid sequence in SEQ ID No. 3 and the variable heavy amino acid sequence in SEQ ID No. 4, and <p>(b)</p> the main species HER2 antibody comprising an amino-terminal leader extension, wherein the amino-terminal leader extension comprises VHS-, wherein from 5% to about 15% of the antibody molecules in the composition comprise an aminoterminal leader extension, as quantified by cation exchange analysis.",
                    "depClaim": "<p>[DC]</p> 2. The composition of claim 1 wherein the amino-terminal leader extension is on a light chain of the antibody comprising the VHS- extension.<p>[DC]</p> 3. The composition of claim 2 wherein the amino-terminal leader extension is on one or two light chains of the antibody comprising the VHS- extension.<p>[DC]</p> 4. The composition of claim 1 wherein the main species HER2 antibody and the antibody comprising the VHS- extension are both intact antibodies.<p>[DC]</p> 5. The composition of claim 1 wherein the main species HER2 antibody comprises the light chain amino acid sequence in SEQ ID No. 15 and the heavy chain amino acid sequence in SEQ ID No. 16.<p>[DC]</p> 6. The composition of claim 5 further comprising: <p>(a)</p> the main species HER2 antibody comprising a C-terminal lysine residue on one or both heavy chains thereof, <p>(b)</p> a deamidated main species HER2 antibody wherein Asn-386 and/or Asn-391 on one or two heavy chains of the main species HER2 antibody are deamidated, and <p>(c)</p> the main species HER2 antibody with one or more oxidized methionine residues at met-254 of SEQ ID No.16.<p>[DC]</p> 7. The composition of claim 1 wherein the amino-terminal leader extension consists of VHS-.<p>[DC]</p> 8. The composition of claim 1 further comprising a glycosylation variant of the main species HER2 antibody, wherein the glycosylation variant is selected from the group consisting of: <p>(a)</p> the main species HER2 antibody comprising a G1 or G2 oligosaccharide structure attached to an Fc region thereof, <p>(b)</p> the main species HER2 antibody comprising a carbohydrate moiety attached to a light chain thereof, <p>(c)</p> the main species HER2 antibody comprising a non-glycosylated heavy chain, and <p>(d)</p> the main species HER2 antibody with a sialidated oligosaccharide structure attached to an Fc region thereof.<p>[DC]</p> 9. The composition of claim 1 wherein the main species antibody binds to the junction between domains I, II and III of HER2.<p>[DC]</p> 10. A pharmaceutical formulation comprising the composition of claim 1 in a pharmaceutically acceptable carrier.<p>[DC]</p> 11. The pharmaceutical formulation of claim 10 which is sterile.",
                    "source": "<p>Source:</p> US7560111B2, Genentech Company: Perjeta® Product"
                },
                {
                    "name": "By Sugar",
                    "color": "green",
                    "claimReason": "“…  N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F) …”",
                    "indClaim": "<p>[IC]</p> 1. A composition comprising adalimumab, wherein more than 25% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).",
                    "depClaim": "<p>[DC]</p> 2. The composition of claim 1, wherein 26-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 3. The composition of claim 1, wherein 35-44% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 4. The composition of claim 1, wherein 30-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 5. The composition of claim 1, wherein less than 70% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 6. The composition of claim 5, wherein 49-69% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 7. The composition of claim 5, wherein 55-65% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 8. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media which has been supplemented with a manganese supplement and a galactose supplement.<p>[DC]</p> 9. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media comprising 0.2-100 M of a manganese supplement and 1-100 mM of a galactose supplement.<p>[DC]</p> 10. The composition of claim 9, wherein the cell culture media comprises a hydrolysate based media or a chemically defined media.<p>[DC]</p> 11. The composition of claim 9, wherein the mammalian cell is a CHO cell.<p>[DC]</p> 12. The pharmaceutical composition of claim 11 and a pharmaceutically acceptable carrier comprising a polyalcohol.<p>[DC]</p> 13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier further comprises polysorbate 80.<p>[DC]</p>  14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.<p>[DC]</p> 15. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.<p>[DC]</p> 16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises mannitol.<p>[DC]</p> 17. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium chloride.<p>[DC]</p> 18. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises polysorbate 80.<p>[DC]</p> 19. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium phosphate.<p>[DC]</p> 20. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for parenteral administration.<p>[DC]</p> 21. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.",
                    "source": "<p>Source:</p> US9255143B2, Abott Biotech Company: Humira® Product"
                },
                {
                    "name": "Crystal",
                    "color": "green",
                    "claimReason": "“ ... A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 …”",
                    "indClaim": "<p>[IC]</p> 1. A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein said crystal has a needle morphology with a length of about 2-500 m and an l/d ratio of about 3 to 30.",
                    "depClaim": "<p>[DC]</p> 2. The crystal according to claim 1, wherein said antibody is selected from the group consisting of: IgG1, IgG2, IgG3 and IgG4 antibodies.<p>[DC]</p> 3. The crystal according to claim 1, wherein said antibody is an IgG1 antibody.<p>[DC]</p> 4. The crystal according to claim 1, wherein the antibody is adalimumab (D2E7).<p>[DC]</p> 5. A pharmaceutical composition comprising: <p>(a)</p> crystals of an anti-hTNFalpha antibody according to claim 1, and <p>(b)</p> at least one pharmaceutical excipient; wherein the composition is provided as a solid, semisolid or liquid formulation, each formulation containing said antibody in crystalline form.<p>[DC]</p> 6. A pharmaceutical composition comprising: <p>(a)</p> crystals of an anti-hTNFalpha antibody according to claim 1, and <p>(b)</p> at least one pharmaceutical excipient, which embeds or encapsulates crystals of said antibody.<p>[DC]</p> 7. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 1 mg/ml.<p>[DC]</p> 8. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 200 mg/ml.<p>[DC]</p> 9. The composition according to claim 5, wherein said excipient comprises at least one polymeric optionally biodegradable carrier or at least one oil or lipid carrier.<p>[DC]</p> 10. The composition according to claim 9, wherein said polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-coglycolic acid) or PLGA, poly (-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl) methacrylamide, poly (organo) phosphazene, poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof.<p>[DC]</p> 11. An injectable liquid composition comprising anti-hTNFalpha antibody crystals according to claim 1 and having an antibody concentration in the range of about 10 to 400 mg/ml.<p>[DC]</p> 12. A crystal slurry comprising anti-hTNFalpha antibody crystals according to claim 1, having an antibody concentration greater than about 100 mg/ml.",
                    "source": "<p>Source:</p> US8436149B2, Abott Biotech Company: Humira® Product"
                },
                {
                    "name": "Chimeric",
                    "color": "green",
                    "claimReason": "“… chimeric antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region …”",
                    "indClaim": "<p>[IC]</p> 1. A chimeric antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, said antibody capable of binding an epitope specific for human tumor necrosis factor TNF, wherein the non-human immunoglobulin variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.",
                    "depClaim": "<p>[DC]</p> 2. An immunoassay method for detecting human TNF in a sample, comprising: <p>(a)</p> contacting said sample with an antibody according to claim 1, or a TNF binding fragment thereof, in detectably labeled form; and <p>(b)</p> detecting the binding of the antibody to said TNF.",
                    "source": "<p>Source:</p> US6284471B1, Janssen Bio. Company: Remicade® Product"
                }
            ]
        },
        {
            "name": "Polynucleotide",
            "color": "yellow",
            "children": [
                {
                    "name": "Vector",
                    "color": "yellow",
                    "claimReason": "“… recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide base sequence selected from the group consisting of the nucleotide base sequence of SEQ ID NO:1 …”",
                    "indClaim": "<p>[IC]</p> 1. An isolated recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide base sequence selected from the group consisting of the nucleotide base sequence of SEQ ID NO:1, the nucleotide base sequence of SEQ ID NO:2, a sequence complementary to any foregoing sequence, an expression-enhancing portion of any foregoing sequence, and combinations thereof.",
                    "depClaim": "<p>[DC]</p> 2. The isolated rEVE polynucleotide molecule according to claim 1, wherein the rEVE polynucleotide molecule comprises an expression-enhancing portion of the sequence of SEQ ID NO:2 selected from the group consisting of the sequence of bases 462-2422 of SEQ ID NO:2 and the sequence of bases 1087-2422 of SEQ ID NO:2.<p>[DC]</p> 3. A recombinant vector comprising a rEVE polynucleotide molecule as described in claim 1.<p>[DC]</p> 4. The recombinant vector according to claim 3, wherein the recombinant vector is a recombinant expression vector.<p>[DC]</p> 5. The recombinant expression vector according to claim 4 selected from the group consisting of a recombinant plasmid expression vector, a recombinant eukaryotic viral expression vector, a recombinant bacteriophage expression vector, a recombinant yeast mini-chromosome expression vector, a recombinant bacterial artificial chromosome expression vector, and a recombinant yeast expression plasmid vector.<p>[DC]</p> 6. The recombinant expression vector according to claim 4, wherein the recombinant expression vector comprises one or more functional recombinant genes encoding one or more recombinant proteins.<p>[DC]</p> 7. The recombinant expression vector according to claim 6, wherein said one or more recombinant proteins is selected from the group consisting of a soluble protein, a membrane protein, a structural protein, a ribosomal protein, an enzyme, a zymogen, an antibody molecule, a cell surface receptor protein, a transcription regulatory protein, a translation regulatory protein, a chromatin protein, a hormone, a cell cycle regulatory protein, a G protein, a neuroactive peptide, an immunoregulatory protein, a blood component protein, an ion gate protein, a heat shock protein, a dihydrofolate reductase (DHFR), an antibiotic resistance protein, a functional fragment of any of the preceding proteins, an epitope-containing fragment of any of the preceding proteins, and combinations thereof.<p>[DC]</p> 8. The recombinant expression vector according to claim 7, wherein the antibody molecule is selected from the group consisting of an anti-TNF- antibody, an anti-EL-selectin antibody, an anti-IL-13 antibody, and a dual variable domain immunoglobulin molecule.<p>[DC]</p> 9. The recombinant expression vector according to claim 8, wherein the anti-TNF- antibody is adalimumab.<p>[DC]</p> 10. The recombinant expression vector according to any one of claims 4-9, wherein said recombinant expression vector comprises at least one copy of a gene encoding a dihydrofolate reductase.<p>[DC]</p> 11. A host cell comprising a vector described in any one of claims 3-9.<p>[DC]</p> 12. The host cell according to claim 11, wherein the host cell is a eukaryotic host cell or a prokaryotic host cell.<p>[DC]</p> 13. The host cell according to claim 12, wherein the host cell is a eukaryotic host cell selected from the group consisting of a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell.<p>[DC]</p> 14. The host cell according to claim 13, wherein the eukaryotic host cell is a mammalian host cell.<p>[DC]</p> 15. The host cell according to claim 14, wherein the mammalian host cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK 293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, and an MDCK cell.<p>[DC]</p> 16. The host cell according to claim 15, wherein the mammalian host cell is a CHO cell.<p>[DC]</p> 17. The host cell according to claim 13, wherein the eukaryotic host cell is a fungal host cell.<p>[DC]</p> 18. The host cell according to claim 17, wherein the fungal host cell is selected from the group consisting of Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida.<p>[DC]</p> 19. The host cell according to claim 18, wherein the Saccaromyces host cell is an S. cerevisiae host cell.<p>[DC]</p> 20. The host cell according to claim 13, wherein the eukaryotic host cell is a protozoan host cell.<p>[DC]</p> 21. The host cell according to claim 20, wherein the protozoan host cell is a Leishmania tarentolae host cell.<p>[DC]</p> 22. A method of producing a recombinant protein of interest comprising transcribing and translating one or more genes encoding the recombinant protein of interest present on a recombinant expression vector described in any of claims 4-9.<p>[DC]</p> 23. The method according to claim 22, wherein said transcribing and translating occur in a cellfree transcription/translation system or in a host cell.<p>[DC]</p> 24. The method according to claim 23, wherein said transcribing and translating occur in a host cell.<p>[DC]</p> 25. The method according claim 24, wherein said host cell is a CHO host cell.<p>[DC]</p> 26. A method of producing a host cell that stably expresses elevated levels of a recombinant protein of interest, comprising: <p>(a)</p>inserting into host cells a recombinant expression vector described in claim 10, growing said host cells in the presence of methotrexate to select for a methotrexate-resistant host cell that expresses the recombinant protein of interest, and isolating said methotrexate-resistant host cell, wherein said isolated methotrexate-resistant host cell expresses the recombinant protein of interest at a level that is higher than that of a methotrexate-sensitive host cell, and wherein said methotrexate-resistant host cell stably expresses an elevated level of the recombinant protein when grown in the presence or in the absence of methotrexate.<p>[DC]</p> 27. The method according to claim 26, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 M.<p>[DC]</p> 28. The method according to claim 26, wherein said host cell is a CHO host cell.<p>[DC]</p> 29. In a dihydrofolate reductase (DHFR)-methotrexate method for amplifying the expression of a recombinant protein of interest encoded on a recombinant expression vector in a host cell, wherein said recombinant expression vector comprises a gene coding for the recombinant protein of interest and a gene encoding DHFR, the improvement wherein said recombinant expression vector also comprises a rEVE polynucleotide molecule as described in claim 1 or claim 2, wherein growth of host cells containing the expression vector in the presence of methotrexate selects for and produces a methotrexate-resistant host cell that stably expresses the recombinant protein of interest at an amplified level when grown in the presence or in the absence of methotrexate.<p>[DC]</p> 30. The method according to claim 29, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 M.<p>[DC]</p> 31. The method according to claim 29, wherein said host cell is a CHO host cell.",
                    "source": "<p>Source:</p> US7935808B2, Abott Biotech Company: Humira® Product"
                },
                {
                    "name": "Sequence",
                    "color": "yellow",
                    "claimReason": "“… comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising …”",
                    "indClaim": "<p>[IC]</p> 1. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).",
                    "depClaim": "<p>[DC]</p> 2. The composition of claim 1, wherein the first polynucleotide and the second polynucleotide are part of the same nucleic acid molecule.<p>[DC]</p> 3. The composition of claim 1, wherein the first polynucleotide and the second polynucleotide are operably linked such that they encode a single-chain antibody.<p>[DC]</p> 4. The composition of claim 3, wherein the single-chain antibody is a single-chain Fv antibody.<p>[DC]</p> 5. The composition of claim 1, which encodes a Fab antibody.<p>[DC]</p> 6. The composition of claim 1, which encodes a Fab antibody.<p>[DC]</p> 7. The composition of claim 1, which encodes a F(ab)2 antibody.<p>[DC]</p> 8. The composition of claim 1, which encodes a fully human antibody.",
                    "source": "<p>Source:</p> US8058418B2, Amgen Company: Xgeva® Product"
                }
            ]
        },
        {
            "name": "Formulation & Composition",
            "color": "blue",
            "children": [
                {
                    "name": "Macro",
                    "color": "blue",
                    "children": [
                        {
                            "name": "Dosage Form",
                            "color": "blue",
                            "claimReason": "“… a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppositor …”",
                            "indClaim": "<p>[IC]</p> 54. A pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less, and a pharmaceutically acceptable carrier, wherein the composition has a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppository.",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Pharmaceutical Carrier",
                            "color": "blue",
                            "claimReason": "“… wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, an isotonic agent, a sugar, a polyalcohol, mannitol, sorbitol, and sodium chloride …”",
                            "indClaim": "<p>[IC]</p> 84. A pharmaceutical composition comprising an isolated human anti-TNF antibody, or antigenbinding portion thereof, and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, an isotonic agent, a sugar, a polyalcohol, mannitol, sorbitol, and sodium chloride, and wherein the antibody or antigen-binding portion thereof, comprises an IgG1 heavy chain, comprises a light chain variable region (LCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                        }
                    ]
                },
                {
                    "name": "Micro (Concentration, PH, Mass, Conducitivity etc)",
                    "color": "blue",
                    "children": [
                        {
                            "name": "Components",
                            "color": "blue"
                        },
                        {
                            "name": "Hydrodynamic diameter",
                            "color": "blue",
                            "claimReason": "“… has a hydrodynamic diameter (Dh) of less than about 4 nm …”",
                            "indClaim": "<p>[IC]</p> 28. An aqueous formulation comprising an antibody, or an antigen-binding fragment, at a concentration of at least about 20 mg/mL, and water, wherein the antibody, or antigen-binding fragment, has a hydrodynamic diameter (Dh) of less than about 4 nm, and wherein the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa.",
                            "depClaim": "<p>[DC]</p> 29. The formulation of claim 28, wherein the antibody has a Dh of less than about 3 nm.<p>[DC]</p> 30. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a chimeric antibody, a human antibody, a humanized antibody, and a domain antibody (dAb).<p>[DC]</p> 31. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is an anti-TNF-alpha or an anti-IL-12 antibody, or antigen-binding fragment thereof.<p>[DC]</p> 32. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of, alemtuzumab, arcitumomab, cetuximab, trastuzumab, imciromab pentetate, capromab pendetide, infliximab, abciximab, rituximab, basiliximab, palivizumab, nofetumomab, omalizumab, daclizumab, ibritumomab tiuxetan, muromonab-CD3, edrecolomab gemtuzumab ozogamicin, golimumab, certolizumab pegol, eculizumab, ustekinumab, panitumumab, tositumomab, I131 tositumomab, and bevacizumab.<p>[DC]</p> 33. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is adalimumab.<p>[DC]</p> 34. The formulation of any one of claims 1, 13, 17, and 28, further comprising a non-ionizable excipient.<p>[DC]</p> 35. The formulation of claim 34, wherein the non-ionizable excipient is selected from the group consisting of a polyol, a non-ionic surfactant, sucrose, trehalose, raffinose, and maltose.<p>[DC]</p> 36. The formulation of claim 35, wherein the polyol is mannitol or sorbitol.<p>[DC]</p> 37. The formulation of claim 35, wherein the non-ionic surfactant is polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.<p>[DC]</p> 38. The formulation of any one of claims 1, 13, 17, and 28, wherein the formulation is stable in a liquid form for at least about 3 months or at least about 12 months.<p>[DC]</p> 39. The formulation of any one of claims 1, 13, 17, and 28, wherein the formulation does not comprise an agent selected from the group consisting of a tonicity modifier, a stabilizing agent, a surfactant, an anti-oxidant, a cryoprotectant, a bulking agent, a lyroprotectant, a basic component, and an acidic component.<p>[DC]</p> 40. The formulation of any one of claims 1, 13, 17, and 28, wherein the formulation is suitable for in vitro or in vivo use.<p>[DC]</p> 41. The formulation of claim 40, wherein the formulation is suitable for administration to a subject via a mode of administration selected from the group consisting of subcutaneous, intravenous, inhalation, intradermal, transdermal, intraperitoneal, and intramuscular.",
                            "source": "<p>Source:</p> US8420081B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "PH Value",
                            "color": "blue",
                            "claimReason": "“… formulation comprising an antibody that binds to VEGF in an arginine acetate buffer at a pH from about 4.5 to about 6.0 …”",
                            "indClaim": "<p>[IC]</p> 24. A pharmaceutical formulation comprising an antibody that binds to VEGF in an arginine acetate buffer at a pH from about 4.5 to about 6.0, and a surfactant, wherein the antibody is bevacizumab.",
                            "depClaim": "<p>[DC]</p> 25. The pharmaceutical formulation of claim 24, wherein the arginine acetate buffer is pH 4.5 to 5.5.<p>[DC]</p> 26. The pharmaceutical formulation of claim 24, wherein the arginine acetate buffer is pH 4.8 to 5.4.<p>[DC]</p> 27. The pharmaceutical formulation of claim 24, wherein the arginine acetate buffer is pH 5.2.<p>[DC]</p> 28. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 25 mm to about 250 mm.<p>[DC]</p> 29. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 50 mm to about 250 mm.<p>[DC]</p> 30. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 75 mm to about 250 mm.<p>[DC]</p> 31. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 100 mm to about 250 mm.<p>[DC]</p> 32. The pharmaceutical formulation of claim 25, wherein the arginine acetate concentration in the buffer is from about 120 mm to about 240 mm.<p>[DC]</p> 33. The pharmaceutical formulation of claim 25, wherein arginine acetate concentration in the buffer is from about 150 mm to about 225 mm.<p>[DC]</p> 34. The pharmaceutical formulation of claim 25, wherein the arginine acetate concentration in the buffer is about 200 mm.<p>[DC]</p> 35. The pharmaceutical formulation of claim 24, wherein the surfactant is polysorbate.<p>[DC]</p> 36. The pharmaceutical formulation of claim 35, wherein the polysorbate is polysorbate 20.<p>[DC]</p> 37. The pharmaceutical formulation of claim 24, wherein the surfactant concentration is from about 0.0001% to about 1.0%.<p>[DC]</p> 38. The pharmaceutical formulation of claim 24, wherein the surfactant concentration is from about 0.01% to about 0.05%.<p>[DC]</p> 39. The pharmaceutical formulation of claim 24, wherein the surfactant concentration is 0.04%.<p>[DC]</p> 40. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 10 mg/ml to about 250 mg/ml.<p>[DC]</p> 41. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 25 mg/ml to about 200 mg/ml.<p>[DC]</p> 42. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 50 mg/ml to about 150 mg/ml.<p>[DC]</p> 43. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 75 mg/ml to about 125 mg/ml.<p>[DC]</p> 44. The pharmaceutical formulation of claim 36, wherein the antibody concentration is about 75 mg/ml to about 125 mg/ml, the arginine acetate buffer is pH 4.8 to 5.4, the arginine acetate concentration in the buffer is from about 150 mM to about 225 mM, and the polysorbate 20 concentration is from about 0.01% to about 0.05%.<p>[DC]</p> 45. The pharmaceutical formulation of claim 44, wherein the antibody concentration is about 100 mg/ml, the arginine acetate buffer is pH 5.2, the arginine acetate concentration in the buffer is about 200 mM, and the polysorbate 20 concentration is 0.04%.<p>[DC]</p> 46. The pharmaceutical formulation of claim 24, wherein the antibody is not subject to prior lyophilization.<p>[DC]</p> 47. The pharmaceutical formulation of claim 24 which is sterile.<p>[DC]</p> 48. The pharmaceutical formulation of claim 24 which is stable upon storage at about 40° C. for at least 28 days.<p>[DC]</p> 49. The pharmaceutical formulation of claim 24 which is aqueous and is administered to a subject.<p>[DC]</p> 50. The pharmaceutical formulation of claim 49, wherein the pharmaceutical formulation is for intravenous (IV), subcutaneous (SQ) or intramuscular (IM) administration.<p>[DC]</p> 51. The pharmaceutical formulation of claim 49, which is for IV administration and the antibody concentration is from about 10 mg/ml to about 250 mg/ml.<p>[DC]</p> 52. The pharmaceutical formulation of claim 49, which is for IV administration and the antibody concentration is from about 50 mg/ml to about 100 mg/ml.<p>[DC]</p> 53. The pharmaceutical formulation of claim 49, which is for SQ administration and the antibody concentration is from about 25 mg/ml to about 250 mg/ml.<p>[DC]</p> 54. The pharmaceutical formulation of claim 49, which is for SQ administration and the antibody concentration is from about 50 mg/ml to about 100 mg/ml.<p>[DC]</p> 55. A vial with a stopper pierceable by a syringe comprising the pharmaceutical formulation of claim 24 inside the vial.<p>[DC]</p> 56. The vial of claim 55 which is stored at about 2-8° C.<p>[DC]</p> 57. The vial of claim 55 which is a 3 cc, 20 cc or 50 cc vial.<p>[DC]</p> 58. The vial of claim 55, wherein the antibody concentration in the formulation is about 75 mg/ml to about 125 mg/ml, the arginine acetate buffer is pH 4.8 to 5.4, the arginine acetate concentration in the buffer is from about 150 mM to about 225 mM, and the surfactant is polysorbate 20 at a concentration from about 0.01% to about 0.05%.<p>[DC]</p> 59. The vial of claim 58, wherein the antibody concentration in the formulation is about 100 mg/ml, the arginine acetate buffer is pH 5.2, the arginine acetate concentration in the buffer is about 200 mM, and the polysorbate 20 concentration is 0.04%.<p>[DC]</p> 60. A stainless steel tank comprising the pharmaceutical formulation of claim 24 inside the tank.<p>[DC]</p> 61. The tank of claim 56 wherein the pharmaceutical formulation is frozen.<p>[DC]</p> 62. The tank of claim 60, wherein the antibody concentration in the formulation is about 75 mg/ml to about 125 mg/ml, the arginine acetate buffer is pH 4.8 to 5.4, the arginine acetate concentration in the buffer is from about 150 mM to about 225 mM, and the surfactant is polysorbate 20 at a concentration from about 0.01% to about 0.05%.<p>[DC]</p> 63. The tank of claim 62, wherein the antibody concentration in the formulation is about 100 mg/ml, the arginine acetate buffer is pH 5.2, the arginine acetate concentration in the buffer is about 200 mM, and the polysorbate 20 concentration is 0.04%.",
                            "source": "<p>Source:</p> US9226961B2, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Aggregation",
                            "color": "blue",
                            "claimReason": "“… <3% aggregates when formulated at a concentration of about 150 mg/mL …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treating a patient suffering from multiple sclerosis, comprising administering to the patient an amount of a daclizumab composition sufficient to provide therapeutic benefit, wherein the daclizumab has two or more of the following: <p>(a)</p> an N-terminal isoform with one pyroglutamate residue and one glutamine residue that comprises 3%-17% of the total daclizumab: <p>(b)</p> an N-linked oligosaccharide profile comprising two main peaks and a minor peak, wherein one of the two main peaks is GO-GlcNAc glycoform present in about 5% to about 20% of the AUC, the other main peak is GO glycoform present in about 70% to about 99.2% of the AUC, and the minor peak is G1 glycoform present in 1% to 9% of the AUC when determined according to the method described in Section 7.6.14, <p>(c)</p> <3% aggregates when formulated at a concentration of about 150 mg/mL.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1 in which the daclizumab composition is administered: <p>(a)</p> subcutaneously; <p>(b)</p> in an amount corresponding to about 1 mg/kg daclizumab, once every two weeks or in an amount corresponding to about 2 mg/kg daclizumab, once every month; <p>(c)</p> for a total of about 24 weeks; or <p>(d)</p> according to any combination of (a)-(c).<p>[DC]</p> 3. The method of claim 2, in which the daclizumab composition is administered in an amount corresponding to 75 mg to 300 mg daclizumab, or 150 mg, or 300 mg.<p>[DC]</p> 4. The method of claim 3 wherein the daclizumab composition is administered subcutaneously in an amount corresponding to 150 mg daclizumab once every month.<p>[DC]</p> 5. The method of claim 3 in which the daclizumab is administered as monotherapy, in which the patient has either failed to respond to prior treatment with interferon-beta or has discontinued prior treatment with interferon-beta.<p>[DC]</p> 7. The method of claim 1 in which the daclizumab has an N-linked glycosylation profile determined according to the method described in Section 7.6.14, in which the total AUC of the peaks in the profile corresponding to non-fucosylated mannose glycosyls is less than about 6% of the total AUC of all peaks in the profile.<p>[DC]</p> 8. The method of claim 4 which is administered for a total of at least 48 weeks.",
                            "source": "<p>Source:</p> US9676860B2, Biogen Company: Zinbryta® Product"
                        },
                        {
                            "name": "Multiple Antibodies",
                            "color": "blue",
                            "claimReason": "“… acidic variants of the main species antibody, wherein the acidic variants include …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treating HER2 positive cancer in a patient comprising administering a pharmaceutical formulation to the patient in an amount effective to treat the cancer, wherein the pharmaceutical formulation comprises a composition comprising a main species HER2 antibody comprising variable light and variable heavy sequences comprising SEQ ID Nos. 3 and 4, respectively, and acidic variants of the main species antibody, wherein the acidic variants include a glycated variant, a deamidated variant, a disulfide reduced variant, a sialylated variant, and a non-reducible variant in a pharmaceutically acceptable carrier.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1 wherein the cancer is breast cancer.<p>[DC]</p> 3. The method of claim 1 wherein the main species antibody and acidic variants have essentially the same pharmacokinetics.<p>[DC]</p> 4. The method of claim 1 wherein the composition comprises less than about 25% acidic variants.<p>[DC]</p> 5. The method of claim 1 wherein the main species HER2 antibody and the acidic variants are intact antibodies.<p>[DC]</p> 6. The method of claim 1 wherein the main species HER2 antibody comprises light chain and heavy chain amino acid sequences comprising SEQ ID Nos. 15 and 16, respectively.<p>[DC]</p> 7. The method of claim 1 wherein the composition further comprises an amino-terminal leader extension variant of the main species antibody.<p>[DC]</p> 8. The method of claim 7 wherein the amino-terminal leader extension comprises VHS-.<p>[DC]</p> 9. The method of claim 7 wherein the amino-terminal leader extension consists of VHS-.<p>[DC]</p> 10. The method of claim 1 wherein the composition further comprises an amino acid sequence variant of the main species HER2 antibody selected from the group consisting of an antibody comprising a C-terminal lysine residue on one or both heavy chains thereof, and an antibody with one or more oxidized methionine residues.",
                            "source": "<p>Source:</p> US9181346B2, Genentech Company: Perjeta® Product"
                        }
                    ]
                }
            ]
        },
        {
            "name": "Treatment",
            "children": [
                {
                    "name": "Treatment for Condition XYZ",
                    "color": "red",
                    "children": [
                        {
                            "name": "In Vivo",
                            "color": "red",
                            "claimReason": "“… method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject …”",
                            "indClaim": "<p>[IC]</p> 9. A method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or antigen-binding portion thereof, with the following characteristics: <p>a)</p> dissociates from human INF with a K off rate constant 1×10-3 s-1 or less, as determined by surface plasmon resonance; <p>b)</p> has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1,4, 5, 7 or 8 or by one to five conservative amino avid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; <p>c)</p> has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US7223394B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "In Vitro",
                            "color": "red",
                            "claimReason": "“… method of treating a subject having a CD38-positive hematological malignancy … wherein the anti-CD38 antibody induces in vitro killing of CD38-expressing cells …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), wherein the anti-CD38 antibody induces in vitro killing of CD38-expressing cells by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC), apoptosis, or in vitro modulation of CD38 enzymatic activity and comprises heavy chain complementarity determining region (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) sequences of SEQ ID NOs: 6, 7 and 8, respectively, and light chain complementarity determining region (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) sequences of SEQ ID NOs: 9, 10 and 11, respectively, wherein the subject is resistant to or has acquired resistance to treatment with at least one chemotherapeutic agent.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the anti-CD38 antibody induces killing of the CD38-expressing cells by ADCC or CDC in vitro.<p>[DC]</p> 3. The method of claim 2, wherein the anti-CD38 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.<p>[DC]</p> 4. The method of claim 3, wherein the anti-CD38 antibody has a biantennary glycan structure with fucose content of about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%.<p>[DC]</p> 5. The method of claim 3, wherein the anti-CD38 antibody comprises a substitution in the antibody Fc at amino acid position 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430, wherein residue numbering is according to the EU index.<p>[DC]</p> 6. The method of claim 1, wherein the anti-CD38 antibody comprises a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5.<p>[DC]</p> 7. The method of claim 6, wherein the anti-CD38 antibody comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13.<p>[DC]</p> 8. The method of claim 1, wherein the CD38-positive hematological malignancy is multiple myeloma, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large Bcell lymphoma (DLBCL), Burkitt's lymphoma (BL), follicular lymphoma (FL) or mantle-cell lymphoma (MCL).<p>[DC]</p> 9. The method of claim 8, wherein the CD38-positive hematological malignancy is DLBCL.<p>[DC]</p> 10. The method of claim 8, wherein the subject is resistant to or has acquired resistance to treatment with a combination of at least one chemotherapeutic agent and an anti-CD20 antibody.<p>[DC]</p> 11. The method of claim 8, wherein the subject has discontinued treatment with at least one chemotherapeutic agent or a combination of at least one chemotherapeutic agent and an anti- CD20 antibody due to side effects.<p>[DC]</p> 12. The method of claim 10 or 11, wherein the anti-CD20 antibody is rituximab (RITUXAN®), ofatumumab (ARZERRA®), veltuzumab, ocrelizumab, obinutuzumab (GA-101), PRO13192 or ocratuzumab (AME-133v).<p>[DC]</p> 13. The method of claim 12, wherein the anti-CD20 antibody is rituximab.<p>[DC]</p> 14. The method of claim 10 or 11, wherein the at least one chemotherapeutic agent is cyclophosphamide, doxorubicin, vincristine, prednisone, ifosfamide, carboplatin or etoposide.<p>[DC]</p> 15. The method of claim 14, wherein the at least one chemotherapeutic agent is a combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).<p>[DC]</p> 16. The method of claim 14, wherein the at least one chemotherapeutic agent is a combination of ifosfamide, carboplatin and etoposide (ICE).<p>[DC]</p> 17. The method of claim 1, wherein the anti-CD38 antibody, cyclophosphamide, doxorubicin, vincristine and prednisone are administered simultaneously, sequentially or separately.<p>[DC]</p> 18. The method of claim 1, wherein the patient is further treated with radiotherapy.",
                            "source": "<p>Source:</p> US9603927B2, Janssen Bio. Company: Darzalex® Product"
                        },
                        {
                            "name": "Sub-population (Ethnicity, Mutations, Weight, Gender?)",
                            "color": "red",
                            "children": [
                                {
                                    "name": "Absence of Condition XYZ",
                                    "color": "red",
                                    "claimReason": "“… who does not have rheumatoid arthritis or cancer …”",
                                    "indClaim": "<p>[IC]</p> 2. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: <p>(a)</p> administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and <p>(b)</p> administering to the human glucocorticosteroid.",
                                    "depClaim": "<p>[DC]</p> 3. The method of claim 2 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone.",
                                    "source": "<p>Source:</p> US8545843B2, Genentech Company: Rituxan® Product"
                                },
                                {
                                    "name": "Age",
                                    "color": "red",
                                    "claimReason": "“… wherein the patient is >60 years old …”",
                                    "indClaim": "<p>[IC]</p> 1. A method of treating a patient with diffuse large cell lymphoma comprising administering anti- CD20 antibody and chemotherapy to the patient, wherein the patient is >60 years old, wherein the chemotherapy comprises CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone), and wherein the anti-CD20 antibody is administered to the patient in combination with stem cell transplantation regimen.",
                                    "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the antibody comprises a chimeric anti-CD20 antibody.3. The method of claim 2, wherein the antibody comprises rituximab.<p>[DC]</p> 4. The method of claim 1, wherein the lymphoma is accompanied by bone marrow involvement.",
                                    "source": "<p>Source:</p> US8821873B2, Genentech Company: Rituxan® Product"
                                }
                            ]
                        },
                        {
                            "name": "Second Line Treatment",
                            "color": "red",
                            "claimReason": "“… has failed NSAID therapy …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has 3 swollen and 3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 24 of the treatment.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein said patient has psoriasis in <3% body surface area prior to the treatment.<p>[DC]</p> 3. The method of claim 1, wherein said patient has psoriasis in 3% body surface area prior to the treatment.",
                            "source": "<p>Source:</p> US8906372B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": " Prerequisites",
                            "color": "red",
                            "claimReason": "“… who does not have rheumatoid arthritis or cancer …”",
                            "indClaim": "<p>[IC]</p> 2. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: <p>(a)</p> administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and <p>(b)</p> administering to the human glucocorticosteroid.",
                            "depClaim": "<p>[DC]</p> 3. The method of claim 2 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone.",
                            "source": "<p>Source:</p> US8545843B2, Genentech Company: Rituxan® Product"
                        },
                        {
                            "name": "W/ Formulation",
                            "color": "red",
                            "claimReason": "“… method treatment, comprising administering to a patient with Crohn's disease a therapeutic amount of a stable, aqueous pharmaceutical formulation comprising from about 20 mg/ml to about 150 mg/ml of natalizumab …”",
                            "indClaim": "<p>[IC]</p> 9. A method treatment, comprising administering to a patient with Crohn's disease a therapeutic amount of a stable, aqueous pharmaceutical formulation comprising from about 20 mg/ml to about 150 mg/ml of natalizumab, about 10 mM phosphate buffer, about 140 mM sodium chloride, and polysorbate 80 present in an amount of about 0.001% to 2% (w/v), wherein the Crohn's disease is treated by administration of the stable, aqueous pharmaceutical formulation.",
                            "depClaim": "<p>[DC]</p> 10. The method of claim 9, wherein the pharmaceutical formulation is administered to the patient by intravenous administration.<p>[DC]</p> 11. The method of 10, wherein the pharmaceutical formulation is administered to the patient over a series of treatments.<p>[DC]</p> 12. The method of claim 9, wherein natalizumab is present in an amount of about 20 mg/mL.<p>[DC]</p> 13. The method of claim 9, wherein the polysorbate 80 is present an amount of about 0.02% (w/v).<p>[DC]</p> 14. The method of claim 9, wherein the formulation has a pH of about 3.0 to about 7.0.<p>[DC]</p> 15. The method of claim 14, wherein the pH is about 5.5 to about 6.5.<p>[DC]</p> 16. The method of claim 15, wherein the pH is about 6.0 ±0.5.<p>[DC]</p> 18. The method of claim 9, wherein the pharmaceutical formulation is administered to the patient by subcutaneous administration.",
                            "source": "<p>Source:</p> US8815236B2, Biogen Company: Tysabri® Product"
                        },
                        {
                            "name": "Treating Signs & Symptons",
                            "color": "red",
                            "claimReason": "“… method of reducing signs and symptoms in a patient with …”",
                            "indClaim": "<p>[IC]</p> 1. A method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising: administering to said patient, in combination with methotrexate, a human anti-TNF antibody, wherein the human anti-TNF antibody is administered subcutaneously in a total body dose of 40 mg once every 13-15 days, and wherein the anti-TNF antibody comprises an IgG1 heavy chain constant region; a variable light (“V L”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.<p>[DC]</p> 3. The method of claim 1, wherein the dosage is administered from a 40 mg dosage unit form.<p>[DC]</p> 4. The method of claim 3, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.",
                            "source": "<p>Source:</p> US9017680B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Treatment with Side Effects",
                            "color": "red",
                            "claimReason": "“… wherein the patient has a grade III hypertensive event resulting from the bevacizumab administration, the method further comprising administering to the patient an antihypertensive agent in an amount sufficient to manage the grade III hypertensive event while continuing to treat the patient with bevacizumab …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treating cancer in a patient comprising administering to the patient an effective amount of bevacizumab, wherein the patient has a grade III hypertensive event resulting from the bevacizumab administration, the method further comprising administering to the patient an antihypertensive agent in an amount sufficient to manage the grade III hypertensive event while continuing to treat the patient with bevacizumab, the continued bevacizumab treatment being carried out without altering the dosage regimen.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the method further comprises administering one or more chemotherapeutic agents.<p>[DC]</p> 3. The method of claim 2, wherein the one or more chemotherapeutic agents is one or more of an alkylating agent, antimetabolite, pyrimidine analog, vinca alkyloid, epipodophyllotoxin, antibiotic, topoisomerase inhibitor, interferon, platinum coordination complex, or taxoid.<p>[DC]</p> 4. The method of claim 3, wherein the one or more chemotherapeutic agents is one or more of a pyrimidine analog, 5-fluorouracil (5-FU), leucovorin, irinotecan, paclitaxel, oxaliplatin, carboplatin, cisplatin, doxorubicin, topotecan, or interferon-alpha.<p>[DC]</p> 5. The method of claim 4, wherein the one or more chemotherapeutic agents is one or more of 5-FU, leucovorin, irinotecan, or oxaliplatin.<p>[DC]</p> 7. The method of claim 2, wherein the cancer is colorectal cancer, rectal cancer, glioblastoma, non-small cell lung cancer, cervical cancer, peritoneum cancer, renal cancer, ovarian cancer, or mesothelioma.<p>[DC]</p> 8. The method of claim 5, wherein the cancer is metastatic colorectal cancer.<p>[DC]</p> 9. The method of claim 6, wherein the cancer is metastatic colorectal cancer.<p>[DC]</p> 10. The method of claim 4, wherein the cancer is metastatic non-small cell lung cancer.<p>[DC]</p> 11. The method of claim 4, wherein the cancer is metastatic cervical cancer.<p>[DC]</p> 12. The method of claim 4, wherein the cancer is metastatic ovarian cancer or metastatic peritoneum cancer.<p>[DC]</p> 13. The method of claim 4, wherein the cancer is metastatic renal cancer.<p>[DC]</p> 14. The method of claim 1, wherein the cancer is glioblastoma.<p>[DC]</p> 15. The method of claim 1, wherein the bevacizumab is administered to the patient bi-weekly at about 10 mg/kg.<p>[DC]</p> 16. The method of claim 4, wherein the patient does not have clinically significant cardiovascular disease prior to the bevacizumab administration.<p>[DC]</p> 17. The method of claim 8, wherein one of the one or more chemotherapeutic agents is 5-FU.<p>[DC]</p> 18. The method of claim 1, wherein the bevacizumab is administered to the patient bi-weekly at about 5 mg/kg.",
                            "source": "<p>Source:</p> US9795672B2, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Improving effectiveness of Treatment",
                            "color": "red",
                            "children": [
                                {
                                    "name": "Improving Succes Rate",
                                    "color": "red",
                                    "claimReason": "“… method for increasing likelihood of effectiveness of breast cancer treatment with humanized anti-ErbB2 antibody huMAb4D5-8, which method comprises administering …”",
                                    "indClaim": "<p>[IC]</p> 1. A method for increasing likelihood of effectiveness of breast cancer treatment with humanized anti-ErbB2 antibody huMAb4D5-8, which method comprises administering a cancer treating dose of said antibody to a human subject diagnosed with breast cancer, wherein an erbB2 gene amplification in breast cancer cells in a tissue sample from the subject has been detected, and wherein the breast cancer cells from the human subject have been found to have a 0 or 1+ score of ErbB2 protein expression by immunohistochemistry.",
                                    "depClaim": "<p>[DC]</p> 2. The method according to claim 1, wherein the breast cancer cells from the human subject have been found to have a 0 or 1+ score of ErbB2 protein expression by immunohistochemistry on a formaldehyde-fixed tissue sample.<p>[DC]</p> 3. The method according to claim 1 wherein the erbB2 gene amplification is detected by detecting fluorescence of a fluorescent-labeled nucleic acid probe hybridized to the gene.<p>[DC]</p> 4. The method according to claim 1, which further comprises administering a cancer treating dose of a chemotherapeutic drug.<p>[DC]</p> 5. The method according to claim 4, wherein the chemotherapeutic drug is a taxoid.<p>[DC]</p> 6. The method according to claim 1 wherein the likelihood of effectiveness increases by about 30%.",
                                    "source": "<p>Source:</p> US7993834B2, Genentech Company: Herceptin® Product"
                                },
                                {
                                    "name": "Preventing Adverce Events",
                                    "color": "red",
                                    "claimReason": "“… method for ameliorating or preventing an adverse effect mediated by the administration of a CD19×CD3 bispecific antibody …”",
                                    "indClaim": "<p>[IC]</p> 32. A method for ameliorating or preventing an adverse effect mediated by the administration of a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, said method comprising: <p>(a)</p> determining the ratio of total B cells to total T cells in a peripheral blood sample from said human patient to identify patients at risk of developing an adverse effect; <p>(b)</p> identifying said human patient as having an increased risk of potential adverse effects when the ratio of B:T cells is about 1:5 or less before treatment; <p>(c)</p> administering a first dose of said antibody for a first period of time to said patient identified in (b), and consecutively; <p>(d)</p> administering a second dose of said antibody for a second period of time; wherein said second dose exceeds said first dose, and wherein said CD19×CD3 bispecific antibody is MT103 (Blinatumomab).",
                                    "depClaim": "<p>[DC]</p> 33. The method of claim 32, wherein said adverse effect is characterized by a neurological reaction.<p>[DC]</p> 34. The method of claim 33, wherein said neurological reaction is one or more selected from the group consisting of: confusion, ataxia, disorientation, dysphasia, aphasia, speech impairment, cerebellar symptoms, tremor, apraxia, seizure, grand mal convulsion, palsy, and balance disorder.",
                                    "source": "<p>Source:</p> US8840888B2, Amgen Company: Blincyto® Product"
                                }
                            ]
                        }
                    ]
                },
                {
                    "name": "Mechanism of Action",
                    "color": "red",
                    "claimReason": "“… method for increasing an immune response to an antigen in a subject …”",
                    "indClaim": "<p>[IC]</p> 1. A method for increasing an immune response to an antigen in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR3 domains are selected from the group consisting of: <p>(a)</p> a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:37; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:35; and <p>(b)</p> a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:38; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:36; and binds to human CTLA-4 with a binding affinity of about 10 8 M1 or greater.",
                    "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:37 and 32, respectively; and a light chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:35 and 29, respectively; <p>(b)</p> a heavy chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs: 37 and 33, respectively; and a light chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs: 35 and 30, respectively; or <p>(c)</p> a heavy chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:38 and 34, respectively; and a light chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:36 and 31, respectively.<p>[DC]</p> 3. The method of claim 2, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:37, 32 and 27, respectively; and a light chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:35, 29 and 24, respectively; <p>(b)</p> a heavy chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:37, 33 and 27, respectively; and a light chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:35, 30 and 25, respectively; or <p>(c)</p> a heavy chain variable region comprising CDR3, CDR2 and CDR1 comprising sequences set forth in SEQ ID NOs:38, 34 and 28, respectively; and a light chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:36, 31 and 26, respectively.<p>[DC]</p> 4. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region derived from a human VH 3-30.3 gene; and <p>(b)</p> a light chain variable region derived from a human VK A-27 gene.<p>[DC]</p> 5. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region derived from a human VH 3-33 gene; and <p>(b)</p> a light chain variable region derived from a human VK L-15 gene.<p>[DC]</p> 6. The method of claim 4, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region CDR3 sequence set forth in SEQ ID NO: 37, and a light chain variable region CDR3 sequence set forth in SEQ ID NO: 35.<p>[DC]</p> 7. The method of claim 5, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region CDR3 sequence set forth in SEQ ID NO: 38, and a light chain variable region CDR3 sequence set forth in SEQ ID NO: 36.<p>[DC]</p> 8. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises at least one heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17, 19 and 23.<p>[DC]</p> 9. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises at least one light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9 and 13.<p>[DC]</p> 10. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7.<p>[DC]</p> 11. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9.<p>[DC]</p> 12. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13.<p>[DC]</p> 13. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 32 and 37, respectively; and <p>(b)</p> a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 24, 29 and 35, respectively.<p>[DC]</p> 14. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 33 and 37, respectively; and <p>(b)</p> a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 25, 30 and 35, respectively.<p>[DC]</p> 15. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 28, 34 and 38, respectively; and <p>(b)</p> a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 26, 31 and 36, respectively.",
                    "source": "<p>Source:</p> US8784815B2, Ono Pharma (BMS) Company: Yervoy® Product"
                },
                {
                    "name": "Depletion of B Cells",
                    "color": "red",
                    "claimReason": "“… method of depleting peripheral blood B cells in a human host …”",
                    "indClaim": "<p>[IC]</p> 1. A method of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active chimeric anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host, wherein the antibody comprises a light chain variable region comprising amino acid residues 23 to 128 of SEQ ID NO: 4, a human immunoglobulin light chain kappa constant region, a heavy chain variable region comprising amino acid residues 20 to 140 of SEQ ID NO: 6, and a human immunoglobulin heavy chain gamma 1 constant region.",
                    "depClaim": "<p>[DC]</p> 2. The method of claim 1 wherein the antibody is administered to the host in four separate infusions of 375 mg/m2 per infusion.<p>[DC]</p> 3. The method of claim 1 wherein the administration of the antibody causes peripheral blood B cells in the host to be depleted for a period in excess of 2 weeks.<p>[DC]</p> 4. A method for depleting peripheral blood B cells in a host in need of such treatment comprising administering an amount of an immunologically active chimeric anti-CD20 sufficient to induce B cell depletion, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6, and the amount of antibody administered comprises four separate infusions of 375 mg/m2.",
                    "source": "<p>Source:</p> US7744877B2, Genentech Company: Rituxan® Product"
                },
                {
                    "name": "Safety",
                    "color": "red",
                    "claimReason": "“… method of reducing the incidence of an adverse event induced by a therapeutic dose …”",
                    "indClaim": "<p>[IC]</p> 24. A method of reducing the incidence of an adverse event induced by a therapeutic dose of an anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof in treating a hyperproliferative disease, in a subject in need thereof comprising administering <p>(i)</p> a dose of an anti-PD-1 monoclonal antibody or an antigen-binding portion thereof and <p>(ii)</p> a subtherapeutic dose of the anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof to the subject, wherein the subject exhibits a reduction in the adverse event after the administration.",
                    "depClaim": "<p>[DC]</p> 25. The method of claim 24, wherein the adverse event induced by the anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof comprises colitis, diarrhea, rash, pruritis, esophagitis, duodenitis, ileitis, or any combination thereof.<p>[DC]</p> 26. The method of claim 24, further comprising administering a non-absorbable steroid to the subject.<p>[DC]</p> 27. The method of claim 26, wherein the non-absorbable steroid is a corticosteroid.<p>[DC]</p> 28. The method of claim 26, wherein the non-absorbable steroid is administered prior to the administration of the anti-PD-1 antibody or antigen-binding portion thereof or the anti-CTLA-4 antibody or antigen-binding portion thereof.<p>[DC]</p> 29. The method of claim 5 or 17, wherein the cancer is selected from melanoma, lung cancer, renal cancer, prostate cancer, breast cancer, colorectal cancer, and fibrosarcoma.<p>[DC]</p> 30. The method of claim 5 or 17, wherein the cancer is bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.<p>[DC]</p> 31. The method of any one of claims 5, 17, and 24, wherein the combination of the anti-PD-1 antibody or antigen-binding portion thereof and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered concurrently as a single composition or as separate compositions.<p>[DC]</p> 32. The method of any one of claims 5, 17, and 24, wherein the combination of the anti-PD-1 antibody or antigen-binding portion thereof and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered sequentially.<p>[DC]</p> 33. The method of any one of claims 5, 17, and 24, wherein the anti-PD-1 antibody or antigenbinding portion thereof cross-competes for binding to human PD-1 with a reference antibody comprising: <p>(a)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 29; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 36; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 43; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 50; <p>(b)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 23; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 30; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 37; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 44; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 51; <p>(c)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 17; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 24; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 31; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 38; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 45; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 52; <p>(d)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 18; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 25; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 32; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 39; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 46; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 53; <p>(e)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 19; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 26; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 33; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 40; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 47; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 54; <p>(f)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 20; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 27; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 34; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 41; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 48; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 55; or <p>(g)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 21; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 28; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 35; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 42; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 49; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 56.<p>[DC]</p> 34. The method of claim 33, wherein the reference antibody comprises: <p>(a)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8; <p>(b)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; <p>(c)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 10; <p>(d)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11; <p>(e)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12; <p>(f)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13; or <p>(g)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth in SEO ID NO: 14.<p>[DC]</p> 35. The method of claim 34, wherein the reference antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.<p>[DC]</p> 36. The method of claim 34, wherein the anti-PD-1 antibody or antigen-binding portion thereof exhibits one or more of the following properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×108 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 37. The method of claim 36, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 5×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 38. The method of claim 37, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 39. The method of claim 36, wherein the anti-PD-1 antibody or antigen-binding portion thereof has the following properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 40. The method of any one of claims 5, 17, and 24, wherein the anti-PD-1 antibody or antigenbinding portion thereof comprises: <p>(a)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 29; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 36; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 43; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 50; <p>(b)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 23; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 30; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 37; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 44; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 51; <p>(c)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 17; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 24; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 31; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 38; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 45; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 52; <p>(d)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 18; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 25; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 32; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 39; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 46; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 53; <p>(e)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 19; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 26; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 33; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 40; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 47; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 54; <p>(f)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 20; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 27; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 34; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 41; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 48; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 55; or <p>(g)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 21; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 28; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 35; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 42; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 49; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 56.<p>[DC]</p> 41. The method of claim 40, wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8; <p>(b)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; <p>(c)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 10; <p>(d)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11; <p>(e)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12; <p>(f)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13; or <p>(g)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 14.<p>[DC]</p> 42. The method of claim 41, wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.<p>[DC]</p> 43. The method of claim 41 wherein the anti-PD-1 antibody or antigen-binding portion thereof has one or more properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×108 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 44. The method of claim 43, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 5×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 45. The method of claim 44, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 46. The method of claim 43, wherein the anti-PD-1 antibody or antigen-binding portion thereof has the following properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 47. The method of claim 40, wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, which comprises EIVLTQSPATLSLSPGERATLSC (SEQ ID NO: 75) containing one amino acid mutation.<p>[DC]</p> 48. The method of any one of claims 5, 17, and 24, wherein the anti-PD-1 antibody or antigenbinding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.<p>[DC]</p> 49. The method of any one of claims 5, 17, and 24, wherein the anti-CTLA-4 antibody is human monoclonal antibody 10D1.",
                    "source": "<p>Source:</p> US9358289B2, Ono Pharma (BMS) Company: Opdivo® Product"
                },
                {
                    "name": "Treatment by which XYZ is achieved",
                    "color": "red",
                    "children": [
                        {
                            "name": "In Vivo",
                            "color": "red",
                            "claimReason": "“… wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 24 of the treatment …”",
                            "indClaim": "<p>[IC]</p> 1. A method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has 3 swollen and 3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 24 of the treatment.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein said patient has psoriasis in <3% body surface area prior to the treatment.<p>[DC]</p> 3. The method of claim 1, wherein said patient has psoriasis in 3% body surface area prior to the treatment.",
                            "source": "<p>Source:</p> US8906373B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "In Vitro",
                            "color": "red"
                        }
                    ]
                },
                {
                    "name": "Regimen",
                    "color": "red",
                    "children": [
                        {
                            "name": "Constant Dose",
                            "color": "red",
                            "children": [
                                {
                                    "name": "SC",
                                    "color": "red",
                                    "claimReason": "“… method for treating rheumatoid arthritis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid arthritis a total body dose of 40 mg of a human anti-TNF antibody once every 13 -15 days …”",
                                    "indClaim": "<p>[IC]</p> 1. A method for treating rheumatoid arthritis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid arthritis a total body dose of 40 mg of a human anti-TNF antibody once every 13 -15 days for a time period sufficient to treat the rheumatoid arthritis, wherein the anti-TNF antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",
                                    "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.<p>[DC]</p> 3. The method of claim 2, wherein the anti-TNF antibody is administered for a period of at least 24 weeks.<p>[DC]</p> 4. The method of claim 1, wherein the anti-TNF antibody is administered for a period of at least 24 weeks.",
                                    "source": "<p>Source:</p> US8889135B2, Abott Biotech Company: Humira® Product"
                                },
                                {
                                    "name": "IV",
                                    "color": "red",
                                    "claimReason": "“… wherein the antibody is administered as two intravenous doses of 1000 mg …”",
                                    "indClaim": "<p>[IC]</p> 1. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNF-inhibitor, comprising administering to the patient an antibody that binds to CD20, wherein the antibody is administered as two intravenous doses of 1000 mg.",
                                    "depClaim": "<p>[DC]</p> None.",
                                    "source": "<p>Source:</p> US7976838B2, Genentech Company: Rituxan® Product"
                                }
                            ]
                        },
                        {
                            "name": "Multi-variable Dose",
                            "color": "red",
                            "children": [
                                {
                                    "name": "SC",
                                    "color": "red",
                                    "claimReason": "“… multiple-variable dose method for inducing clinical remission of Crohn's disease ... comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNF antibody administered to the subject within a day; and a second dose of 80 mg of the antibody administered to the subject within a day …”",
                                    "indClaim": "<p>[IC]</p> 1. A multiple-variable dose method for inducing clinical remission of Crohn's disease in a subject in need thereof, comprising subcutaneously administering to the subject: <p>(a)</p> a first dose of 160 mg of a recombinant human anti-TNF antibody administered to the subject within a day; and <p>(b)</p> a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose; wherein the antibody comprises: <p>(c)</p> a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; and <p>(d)</p> a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3.",
                                    "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1.<p>[DC]</p> 3. The method of claim 2, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region.<p>[DC]</p> 4. The method of claim 3, wherein the antibody is adalimumab.<p>[DC]</p> 5. The method of claim 1, wherein the method further comprises administering to the subject a subsequent subcutaneous injection of 40 mg of the antibody two weeks following administration of the second dose.<p>[DC]</p> 6. The method of claim 5, wherein the method further comprises administering to the subject additional subsequent subcutaneous injections of 40 mg of the antibody, wherein the subsequent subcutaneous injections are administered two weeks apart.<p>[DC]</p> 7. The method of claim 5, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1.<p>[DC]</p> 8. The method of claim 6, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1.<p>[DC]</p> 9. The method of claim 7, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region.<p>[DC]</p> 10. The method of claim 8, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region.<p>[DC]</p> 11. The method of claim 9, wherein the antibody is adalimumab.<p>[DC]</p> 12. The method of claim 10, wherein the antibody is adalimumab.<p>[DC]</p> 13. The method of claim 1, wherein each subcutaneous injection is administered to the subject using a prefilled syringe.<p>[DC]</p> 14. The method of claim 1, wherein the subject in need thereof has a Crohn's Disease Activity Index (CDAI) of 220-450.",
                                    "source": "<p>Source:</p> US8961973B2, Abott Biotech Company: Humira® Product"
                                },
                                {
                                    "name": "IV",
                                    "color": "red",
                                    "claimReason": "“… administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab …”",
                                    "indClaim": "<p>[IC]</p> 1. A method of treating rheumatoid arthritis in a human comprising: <p>(a)</p> administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and <p>(b)</p> administering to the human methotrexate.",
                                    "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein each administration of the rituximab is a dose in the range from about 250 mg/m2 to about 1000 mg/m2.<p>[DC]</p> 3. The method of claim 1, comprising administering to the human a glucocorticosteroid.<p>[DC]</p> 4. The method of claim 1, comprising administering an initial dose of the rituximab followed by a subsequent dose, where the mg/m2 dose of the rituximab in the subsequent dose exceeds the mg/m2 dose of the rituximab in the initial dose.",
                                    "source": "<p>Source:</p> US7820161B1, Genentech Company: Rituxan® Product"
                                }
                            ]
                        },
                        {
                            "name": "Dose Dependent on XYZ",
                            "color": "red"
                        },
                        {
                            "name": "Administration Frequency",
                            "color": "red",
                            "claimReason": "“… comprising administering subcutaneously … 40mg ... 13-15 days ...”",
                            "indClaim": "<p>[IC]</p> 1. A method for treating ulcerative colitis in a human subject, comprising administering subcutaneously to a human subject having ulcerative colitis a total body dose of 40 mg of a human anti-TNF antibody once every 13-15 days for a time period sufficient to treat the ulcerative colitis, wherein the anti-TNF antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6and a CDR3 having the amino acid sequence of SEQ ID NO:4.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.<p>[DC]</p> 3. The method of claim 1, wherein the human subject has had an unwanted immune response to a chimeric or humanized anti-TNF antibody.<p>[DC]</p> 4. The method of claim 3, wherein the human anti-TNF antibody is administered for a period of at least 24 weeks.<p>[DC]</p> 5. The method of claim 2, wherein the anti-TNF antibody is administered for a period of at least 24 weeks.<p>[DC]</p> 6. The method of claim 1, wherein the anti-TNF antibody is administered for a period of at least 24 weeks.",
                            "source": "<p>Source:</p> US8974790B2, Abott Biotech Company: Humira® Product"
                        }
                    ]
                },
                {
                    "name": "Administration in Combination",
                    "color": "red",
                    "claimReason": "“… wherein the anti-TNF antibody is administered in combination with methotrexate …”",
                    "indClaim": "<p>[IC]</p> 1. A method for treating rheumatoid arthritis in a human subject, comprising administering subcutaneously to a human subject having rheumatoid arthritis a total body dose of 40 mg of a human anti-TNF antibody once every 13-15 days for a time period sufficient to treat the rheumatoid arthritis, wherein the anti-TNF antibody comprises: an IgG1 heavy chain constant 106 region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4, wherein the human subject achieves an ACR20.",
                    "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.<p>[DC]</p> 3. The method of claim 1, wherein the anti-TNF antibody is administered for a period of at least 24 weeks.<p>[DC]</p> 4. The method of claim 2, wherein the anti-TNF antibody is administered for a period of at least 24 weeks.<p>[DC]</p> 5. The method of claim 1, wherein the anti-TNF antibody is administered in combination with methotrexate.<p>[DC]</p> 6. The method of claim 2, wherein the anti-TNF antibody is administered in combination with methotrexate.<p>[DC]</p> 7. The method of claim 3, wherein the anti-TNF antibody is administered in combination with methotrexate.<p>[DC]</p> 8. The method of claim 4, wherein the anti-TNF antibody is administered in combination with methotrexate.",
                    "source": "<p>Source:</p> US9546212B2, Abott Biotech Company: Humira® Product"
                },
                {
                    "name": "Inhibiting XYZ",
                    "color": "red",
                    "children": [
                        {
                            "name": "In Vivo",
                            "color": "red",
                            "claimReason": "“… method for inhibiting radiographic disease progression in a human subject having erosive polyarthritis …”",
                            "indClaim": "<p>[IC]</p> 1. A method for inhibiting radiographic disease progression in a human subject having erosive polyarthritis associated with a disorder in which TNF activity is detrimental, comprising administering to the subject having erosive polyarthritis an isolated human anti-TNF antibody, or antigen-binding portion thereof, such that radiographic disease progression is inhibited in the subject, wherein a Total Sharp Score (TSS) of the subject is either maintained or decreased following administration of the human anti-TNF antibody, or antigen-binding portion thereof, wherein the human anti-TNF antibody, or an antigen-binding portion thereof, dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the human anti-TNF antibody is golimumab, or an antigenbinding portion thereof.<p>[DC]</p> 3. The method of claim 1, wherein the human anti-TNF antibody, or an antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.<p>[DC]</p> 4. The method of claim 1, wherein the human anti-TNF antibody is adalimumab, or an antigenbinding portion thereof.<p>[DC]</p> 5. The method of claim 1, wherein the human anti-TNF antibody, or antigen-binding portion thereof, is administered to the subject on a biweekly dosing regimen.<p>[DC]</p> 6. The method of claim 1, further comprising administering an additional therapeutic agent to the subject.<p>[DC]</p> 7. The method of claim 6, wherein the additional therapeutic agent is methotrexate.",
                            "source": "<p>Source:</p> US8715664B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "In Vitro",
                            "color": "red",
                            "claimReason": "“… method for inhibiting human TNF activity in vitro …”",
                            "indClaim": "<p>[IC]</p> 1. A method for inhibiting human TNF activity in vitro comprising contacting human TNF with an isolated antibody such that human TNF activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less.",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                        }
                    ]
                },
                {
                    "name": "Vaccine",
                    "color": "red",
                    "claimReason": "“… method of conferring persistent immunity to tumor relapse in a subject in need thereof …”",
                    "indClaim": "<p>[IC]</p> 21. A method of conferring persistent immunity to tumor relapse in a subject in need thereof comprising administering to the subject a combination of a dose of an anti-PD-1 monoclonal antibody or an antigen-binding portion thereof and a dose of an anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof, wherein the combination of the anti-PD-1 antibody or antigen-binding portion thereof and the anti-CTLA-4 antibody or antigen-binding portion thereof confers persistent immunity to tumor relapse.",
                    "depClaim": "<p>[DC]</p> 22. The method of claim 21, wherein the dose of the anti-PD-1 antibody or antigen-binding portion thereof is a therapeutic dose and the dose of the anti-CTLA-4 antibody or antigen-binding portion thereof is a subtherapeutic dose.<p>[DC]</p> 23. The method of claim 21, wherein the dose of the anti-PD-1 antibody or antigen-binding portion thereof is a subtherapeutic dose and the dose of the anti-CTLA-4 antibody or antigen-binding portion thereof is a subtherapeutic dose.",
                    "source": "<p>Source:</p> US9358289B2, Ono Pharma (BMS) Company: Opdivo® Product"
                }
            ]
        },
        {
            "name": "Prevention",
            "color": "orange",
            "claimReason": "“… method of preventing a RSV infection or a symptom thereof in a human subject …”",
            "indClaim": "<p>[IC]</p> 1. A method of preventing a RSV infection or a symptom thereof in a human subject, said method comprising administering to the subject a prophylactically effective amount of an aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 40 mg/ml of palivizumab, or an antigen-binding fragment thereof; and (b) histidine, wherein said formulation does not comprise mannitol.",
            "depClaim": "<p>[DC]</p> 4. The method of claim 1 or 3, wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 50 mg/ml, at least 55 mg/mi, at least 60 mg/ml, at least 70 mg/ml, or at least 75 mg/ml.<p>[DC]</p> 5. The method of claim 1 or 3, wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 75 mg/mi, at least 80 mg/mi or at least 85 mg/ml.<p>[DC]</p> 6. The method of claim 1 or 3, wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 90 mg/mi, at least 95 mg/ml or at least 100 mg/ml.<p>[DC]</p> 7. The method of claim 1, 2 or 3, wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 125 mg/mi or at least 150 mg/ml.<p>[DC]</p> 8. The method of claim 1 or 3, wherein said formulation comprises histidine at a concentration of about 1 mM to about 100 mM.<p>[DC]</p> 9. The method of claim 1 or 3, wherein said formulation comprises histidine at a concentration of about 10 mM to about 50 mM.<p>[DC]</p> 10. The method of claim 1 or 3, wherein said formulation is substantially free of surfactants and inorganic salts.<p>[DC]</p> 12. The method of claim 10, wherein said formulation is substantially free of other excipients.<p>[DC]</p> 14. The method of claim 1 or 3, wherein said formulation further comprises an excipient other than a surfactant.<p>[DC]</p> 15. The method of claim 10, wherein said formulation further comprises an excipient other than a surfactant.<p>[DC]</p> 17. The method of claim 14, wherein said excipient is glycine.<p>[DC]</p> 18. The method of claim 15, wherein said excipient is glycine.<p>[DC]</p> 19. The method of claim 17, wherein glycine is at a concentration of less than 150 mM, less than100 mM or less than 50 mM.<p>[DC]</p> 20. The method of claim 18, wherein glycine is at a concentration of less than 150 mM, less than 100 mM or less than 50 mM.<p>[DC]</p> 21. The method of claim 19, wherein glycine is at a concentration of less than 3 mM or less than 2 mM.<p>[DC]</p> 22. The method of claim 20, wherein glycine is at a concentration of less than 3 mM or less than 2 mM.<p>[DC]</p> 23. The method of claim 1 or 3, wherein said formulation has a pH of between about 5.5 to about 7.0.<p>[DC]</p> 24. The method of claim 23, wherein said formulation has a pH of between about 5.5 to about 6.5.<p>[DC]</p> 30. The method of claim 14, wherein said excipient is a saccharide.<p>[DC]</p> 31. The method of claim 30, wherein said saccharide is sucrose.<p>[DC]</p> 32. The method of claim 14, wherein said excipient is a polyol other than mannitol.<p>[DC]</p> 33. The method of claim 32, wherein said polyol is polysorbate.<p>[DC]</p> 34. The method of claim 1, 2 or 3, wherein said aqueous carrier is distilled water.<p>[DC]</p> 37. The method of claim 1, 2 or 3, wherein said formulation is homogenous.<p>[DC]</p> 38. The method of claim 1, 2 or 3, wherein said palivizumab or an antigen-binding fragment thereof is stable at 40° C. for at least 100 days as determined by High Performance Size Exclusion Chromatography (HPSEC).<p>[DC]</p> 39. The method of claim 1, 2 or 3, wherein said palivizumab or palivizumab antigen-binding fragment is stable at about ambient temperature for at least 1 year as determined by HPSEC.<p>[DC]</p> 40. The method of claim 1, 2 or 3, wherein said palivizumab or palivizumab antigen-binding fragment is stable at 40° C. for at least 3 years as determined by HPSEC.<p>[DC]</p> 41. The method of claim 1, 2 or 3, wherein less than 2% of said palivizumab or palivizumab antigen-binding fragment forms an aggregate as measured by HPSEC.<p>[DC]</p> 42. The method of claim 1 or 2, which has been prepared by a process in which, for each step of said process, said palivizumab or palivizumab antigen-binding fragment is in an aqueous phase.<p>[DC]</p> 43. The method of claim 1 or 2, which has been prepared by a process that does not have a drying step.<p>[DC]</p> 44. The method of claim 1 or 2, which has been prepared by a process that does not have a lyophilization step.<p>[DC]</p> 45. The method of claim 10, wherein said formulation comprises histidine at a concentration of 1 mM to 100 mM.<p>[DC]</p> 46. The method of claim 45, wherein said formulation is substantially free of other excipients.<p>[DC]</p> 47. The method of claim 8, wherein said formulation has a pH of between about 5.5 to about 7.0.<p>[DC]</p> 48. The method of claim 45, wherein said formulation has a pH of between about 5.5 to about 7.0.<p>[DC]</p> 49. The method of claim 46, wherein said formulation has a pH of between about 5.5 to about 7.0.<p>[DC]</p> 51. The method of claim 1, 2 or 3, wherein said formulation is administered parenterally or intranasally.<p>[DC]</p> 53. The method of claim 51, wherein said prophylactically effective amount is a dose of 15 mg/kg.<p>[DC]</p> 55. The method of claim 53, further comprising administering another therapy.<p>[DC]</p> 57. The method of claim 1, 2, 3 or 29, wherein said human subject is a human in an nursing home, a human in an orphanage, a human with cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency, or a human who has had a bone marrow transplant.<p>[DC]</p> 58. The method of claim 1, 2, 3 or 29, wherein said human subject is a human infant.<p>[DC]</p> 59. The method of claim 1, 2, 3 or 29, wherein said human subject is a human infant born prematurely or a human infant susceptible to an RSV infection.<p>[DC]</p> 60. The method of any one of claims 1, 2, 3 or 29, wherein said formulation is administered by a nebulizer or inhaler.",
            "source": "<p>Source:</p> US7294336B2, MedImmune Company: Synagis® Product"
        },
        {
            "name": "Diagnostics",
            "color": "aqua",
            "children": [
                {
                    "name": "Detecting (e.g. TNF)",
                    "color": "aqua",
                    "children": [
                        {
                            "name": "In Vivo",
                            "color": "aqua",
                            "claimReason": "“… method of detecting human TNF (hTNF) in a biological sample …”",
                            "indClaim": "<p>[IC]</p> 2. A method of detecting human TNF (hTNF) in a biological sample, said method comprising contacting the biological sample with an isolated human antibody, or an antigen-binding portion thereof, and detecting either an antibody, or antigen-binding portion thereof, bound to hTNF or an unbound antibody, or antigen-binding portion thereof, to thereby detect hTNF in the biological sample, wherein the human antibody, or antigen-binding portion thereof, dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less.",
                            "depClaim": "<p>[DC]</p> 3. The method of claim 2, wherein detection of the hTNF is performed using an immunoassay.<p>[DC]</p> 4. The method of claim 3, wherein the immunoassay is selected from the group consisting of an enzyme linked immunosorbent assay, a radioimmunoassay, tissue histochemistry, and a competition immunoassay.<p>[DC]</p> 5. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×108 M or less.<p>[DC]</p> 6. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×109 M or less.<p>[DC]</p> 7. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 5×1010 M or less.<p>[DC]</p> 8. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, dissociates from human TNF with a Koff rate constant of 5×104 s1 or less.<p>[DC]</p> 9. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, dissociates from human TNF with a Koff rate constant of 1×104 s1 or less.<p>[DC]</p> 10. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, inhibits human TNF-induced expression of ELAM-1 in human umbilical vein endothelial cells.<p>[DC]</p> 11. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, comprises a light chain variable region (LCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.<p>[DC]</p> 12. The method of claim 1 or 2, wherein the isolated human antibody, or an antigen-binding portion thereof, has a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.<p>[DC]</p> 13. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, has an IgG1 heavy chain constant region.<p>[DC]</p> 14. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, has an IgG4 heavy chain constant region.<p>[DC]</p> 15. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, has a kappa light chain constant region.<p>[DC]</p> 16. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, is a Fab fragment.<p>[DC]</p> 17. The method of claim 1 or 2, wherein the isolated human antibody, or antigen-binding portion thereof, is a single chain Fv fragment.",
                            "source": "<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "In Vitro",
                            "color": "aqua"
                        }
                    ]
                }
            ]
        },
        {
            "name": "Competition",
            "color": "navy",
            "children": [
                {
                    "name": "Cross Competition",
                    "color": "navy",
                    "claimReason": "“… which binds to the same epitope on human PD-1 as does a reference antibody, or antigen-binding portion thereof …”",
                    "indClaim": "<p>[IC]</p> 5. A method for treating a cancer in a subject comprising administering to the subject an anti-PD-1 monoclonal antibody, or an antigen-binding portion thereof, which binds to the same epitope on human PD-1 as does a reference antibody, or antigen-binding portion thereof, comprising: <p>(a)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: I and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 8; <p>(b)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 2 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 9; <p>(c)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 10; <p>(d)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 11; <p>(e)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 5 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 12; <p>(f)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 13; or <p>(g)</p> a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 14.",
                    "depClaim": "<p>[DC]</p> 6. The method of claim 5, wherein the reference antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 11.",
                    "source": "<p>Source:</p> US9492540B2, Ono Pharma (BMS) Company: Opdivo® Product"
                },
                {
                    "name": "Affinity Competition",
                    "color": "navy",
                    "claimReason": "“… that binds with higher affinity to a human RANKL polypeptide as shown in SEQ ID NO. 13 than to a murine RANKL polypeptide …”",
                    "indClaim": "<p>[IC]</p> 1. A purified antibody that binds with higher affinity to a human RANKL polypeptide as shown in SEQ ID NO. 13 than to a murine RANKL polypeptide as shown in SEQ ID NO. 11.",
                    "depClaim": "<p>[DC]</p> 2. An antibody according to claim 1 which is a monoclonal antibody.<p>[DC]</p> 3. A method of producing a monoclonal antibody according to claim 2, said method comprising culturing a cloned hybridoma cell that produces said antibody.<p>[DC]</p> 4. A method of producing a monoclonal antibody according to claim 2, said method comprising injecting into the peritoneal cavity of a rodent a cloned hybridoma cell that produces said antibody.<p>[DC]</p> 5. A cloned hybridoma cell that produces a monoclonal antibody according to claim 2.<p>[DC]</p> 6. A composition comprising an antibody according to claim 1.",
                    "source": "<p>Source:</p> US6740522B2, Amgen Company: Prolia® Product"
                }
            ]
        },
        {
            "name": "Drug Delivery Devices",
            "color": "fuchsia",
            "children": [
                {
                    "name": "Administration Device (General & Treatment specific)",
                    "color": "fuchsia",
                    "children": [
                        {
                            "name": "Components",
                            "color": "fuchsia",
                            "claimReason": "“… syringe plunger comprising: a pressurizer disposed at a proximal end; and a distal end bifurcated into a first plunger arm …”",
                            "indClaim": "<p>[IC]</p> 1. A syringe plunger formed of a polymeric material, the syringe plunger comprising: a pressurizer disposed at a proximal end; and a distal end bifurcated into a first plunger arm having a first conical surface and a second conical surface, and a second plunger arm having a first conical surface and a second conical surface, the distal end including: a first contact surface defined by the first conical surface of the first plunger arm and the first conical surface of the second plunger arm, the first contact surface configured to initially contact a firing engagement mechanism, the first contact surface disposed at a first angle of between about 40° and about 80° relative to a longitudinal axis of the syringe plunger, and a second contact surface defined by the second conical surface of the first plunger arm and the second conical surface of the second plunger arm, the second contact surface configured to contact the firing engagement mechanism subsequent to contact by the first contact surface.",
                            "depClaim": "<p>[DC]</p> 2. The syringe plunger of claim 1, wherein the firing engagement mechanism is configured to engage the first and second contact surfaces of the plunger arms, the firing engagement mechanism actuating the syringe plunger when the firing engagement mechanism is activated by a minimum force of between about 5 N and about 25 N.<p>[DC]</p> 3. The syringe plunger of claim 2, wherein, upon actuation of the syringe plunger, the pressurizer of the syringe plunger pressurizes a substance in a syringe barrel and causes the substance to be expelled from the syringe barrel.<p>[DC]</p> 4. The syringe plunger of claim 1, wherein the polymeric material of the syringe plunger has a flexural modulus of between about 2,000 MPa and about 5,500 MPa.<p>[DC]</p> 5. The syringe plunger of claim 1, wherein the first and second contact surfaces have a surface texture that is substantially rough.<p>[DC]</p> 6. The syringe plunger of claim 1, wherein the first and second contact surfaces have a surface texture that is substantially smooth.<p>[DC]</p> 7. The syringe plunger of claim 1, wherein the second contact surface is disposed at a second angle of about 6°-38° relative to the longitudinal axis of the syringe plunger.<p>[DC]</p> 8. The syringe plunger of claim 1, wherein the second contact surface is disposed at a second angle of about 8°-25° relative to the longitudinal axis of the syringe plunger.<p>[DC]</p> 9. The syringe plunger of claim 1, wherein the first and second plunger arms are separated by a third angle of between about 0.5° and about 2.0°.<p>[DC]</p> 10. The syringe plunger of claim 1, wherein the first and second plunger arms are separated by a distance of between about 2.55 mm and about 4.25 mm.<p>[DC]</p> 11. The syringe plunger of claim 1, wherein the first and second plunger arms are separated by a distance of about 3.05 mm.<p>[DC]</p> 12. The syringe plunger of claim 1, wherein the polymeric material is selected from the group consisting of thermoplastic materials and thermosetting materials.<p>[DC]</p> 13. The syringe plunger of claim 12, wherein the thermoplastic materials are selected from the group consisting of polyacetal, polycarbonate, polyacrylate, polyamide, polyester, acryonitrilebutadiene - styrene (ABS), polyvinyl chloride (PVC) and their copolymers, terpolymers, and filled composites thereof.<p>[DC]</p> 14. The syringe plunger of claim 13, wherein the polyacetal materials are selected from the group consisting of acetal homopolymers, copolymers, and filled materials thereof.<p>[DC]</p> 15. The syringe plunger of claim 14, wherein the filled materials are glass sphere filled or glass fiber filled.<p>[DC]</p> 16. The syringe plunger of claim 12, wherein the thermosetting materials are selected from the group consisting of epoxy, acrylic, urethane, ester, vinyl ester, epoxy-polyester, acrylic-urethane, and flurovinyl.<p>[DC]</p> 17. The syringe plunger of claim 16, wherein the acrylic material comprises a reactive functionality selected from the group consisting of an acid, a hydroxyl group, and an epoxy group.<p>[DC]</p> 18. The syringe plunger of claim 16, wherein the epoxy material comprises a reactive functionality that can be cured by a method selected from the group consisting of visible, ultraviolet and thermal crosslinking.<p>[DC]</p> 19. The syringe plunger of claim 12, wherein the thermosetting materials are selected from the group consisting of an epoxy homopolymer, copolymer or filled composite thereof.<p>[DC]</p> 20. The syringe plunger of claim 1, wherein the first contact surface has an open segment between the first and second plunger arms.<p>[DC]</p> 21. The syringe plunger of claim 1, wherein the first and second plunger arms have a mid point fixed configuration.<p>[DC]</p> 22. The syringe plunger of claim 1, wherein the first and second plunger arms have a top point fixed configuration.",
                            "source": "<p>Source:</p> US8636704B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Operation",
                            "color": "fuchsia",
                            "claimReason": "“… method for operating an automatic injection device, the method comprising: operating an actuating bias member to move a plunger …”",
                            "indClaim": "<p>[IC]</p> 15. A method for operating an automatic injection device, the method comprising: operating an actuating bias member to move a plunger including a projecting region comprising an upper solid portion, a lower solid portion and one or more flexible elbows on either side of a central void provided between the upper and lower solid portions of the plunger, wherein the projecting region is in a projecting position when the one or more elbows project outwardly from the central void and in a collapsed position when the one or more elbows are collapsed inwardly toward the central void; and engaging one end of a syringe with the plunger to drive the syringe from a first position relative to a housing in which a needle coupled to another end of the syringe is shrouded by the housing to a second position relative to the housing in which the needle projects from the housing; wherein the projecting region of the plunger is in the projecting position prior to entering the syringe and wherein the projecting region is in the collapsed position inside the syringe for applying an expulsion force to a bung in the syringe in order to compress a liquid dose in the syringe and cause expression of the liquid dose from the syringe, wherein a collapsing movement of the projecting region toward the central void from the projecting position outside the syringe to the collapsed position inside the syringe causes an elongation in the length of the plunger.",
                            "depClaim": "<p>[DC]</p> 16. The method as claimed in claim 15, wherein the central void is a longitudinally extending slit.<p>[DC]</p> 17. The method as claimed in claim 15, further comprising: holding the syringe in the first position relative to the housing using a return bias member acting between the housing and another end of the syringe, until the actuating bias member is released.<p>[DC]</p> 18. The method as claimed in claim 15, wherein the housing is fixed relative to the syringe.<p>[DC]</p> 19. The method as claimed in claim 15, wherein the plunger is molded integrally.",
                            "source": "<p>Source:</p> US8162887B2, Abott Biotech Company: Humira® Product"
                        }
                    ]
                },
                {
                    "name": "Training Device",
                    "color": "fuchsia",
                    "claimReason": "“… needleless automatic injection training device for training a recipient on administration of a substance …”",
                    "indClaim": "<p>[IC]</p> 1. A needleless automatic injection training device for training a recipient on administration of a substance, the training device comprising: a cylindrical outer housing; an activation button operatively coupled to the housing; an audible mechanism to convey audible information to a user concerning operation of the training device; a visual indicator, wherein the visual indicator conveys information to a user after a predetermined time period from depression of the activation button to simulate completion of an injection; and wherein the training device is unsuitable for administering a substance.",
                    "depClaim": "<p>[DC]</p> 2. The training device of claim 1, wherein the audible information is conveyed in response to an activation of the activation button.<p>[DC]</p> 3. The training device of claim 1, further comprising a visual indicator to convey visual information to the user.<p>[DC]</p> 4. The training device of claim 3, wherein the visual indicator conveys the visual information to the user in response to activation of the activation button.<p>[DC]</p> 5. The training device of claim 1, wherein the activation button initiates an operation of the training device.<p>[DC]</p> 6. The training device of claim 1, further comprising a syringe actuation component disposed within the housing, a transparent cylinder disposed within the housing, a rod movably disposed in the cylinder, and the visual indicator disposed on the rod, wherein depression of the activation button advances the syringe actuation component to expel air from the training device.<p>[DC]</p> 7. The training device of claim 1, wherein the training device lacks a member corresponding to a needle.",
                    "source": "<p>Source:</p> US9572938B2, Abott Biotech Company: Humira® Product"
                }
            ]
        },
        {
            "name": "Article of Manufacture",
            "color": "olive",
            "claimReason": "“… vial containing a formulation comprising a lyophilized mixture of a recombinant humanized HER2 monoclonal antibody, a lyoprotectant, and a buffer …”",
            "indClaim": "<p>[IC]</p> 14. A vial containing a formulation comprising a lyophilized mixture of a recombinant humanized HER2 monoclonal antibody, a lyoprotectant, and a buffer.",
            "depClaim": "<p>[DC]</p> 15. The vial of claim 14 which is a 3, 5, 10, 20, 50, or 100 cc vial.<p>[DC]</p> 16. The vial of claim 14 wherein the antibody is huMAb4D5-8.<p>[DC]</p> 17. The vial of claim 14 wherein the pH of the formulation is from 5-7.<p>[DC]</p> 18. The vial of claim 17 wherein the pH of the formulation is 6.0.<p>[DC]</p> 19. The vial of claim 14 wherein the buffer is histidine, phosphate, Tris, citrate, succinate, or other organic acid.",
            "source": "<p>Source:</p> US7682609B2, Genetech Company: Herceptin® Product"
        },
        {
            "name": "Methodology",
            "color": "teal",
            "children": [
                {
                    "name": "Biomarkers",
                    "color": "teal",
                    "children": [
                        {
                            "name": "Efficacy of Treatment",
                            "color": "teal",
                            "claimReason": "“… A method for determining the efficacy of a human anti-TNF antibody, or an antigen-binding portion thereof, for treating a subject having ankylosing spondylitis (AS), said method comprising determining a level of a collagen degradation biomarker …”",
                            "indClaim": "<p>[IC]</p> 7. A method for determining the efficacy of a human anti-TNF antibody, or an antigen-binding portion thereof, for treating a subject having ankylosing spondylitis (AS), said method comprising determining a level of a collagen degradation biomarker and a synovitis biomarker in a sample(s) obtained from the subject following administration of the human anti-TNF antibody, or antigenbinding portion thereof; and comparing the level of the collagen degradation biomarker and the synovitis biomarker in the sample(s) to a baseline level of the collagen degradation biomarker and the synovitis biomarker, wherein a lower level of the collagen degradation biomarker and the synovitis biomarker in the sample(s) relative to the baseline level of the collagen degradation biomarker and the synovitis biomarker indicates that the human anti-TNF antibody, or an antigen-binding portion thereof, is efficacious for the treatment of AS in the subject.",
                            "depClaim": "<p>[DC]</p> 8. The method of claim 7, wherein the collagen degradation biomarker is type II collagen Ctelopeptide (CTX-II).<p>[DC]</p> 9. The method of claim 8, wherein the collagen degradation biomarker is urinary type II collagen C-telopeptide (CTX-II).<p>[DC]</p> 10. The method of claim 7, wherein the synovitis biomarker is matrix metalloprotease 3 (MMP3).<p>[DC]</p> 11. The method of claim 10, wherein the synovitis biomarker is serum metalloprotease 3 (MMP3).<p>[DC]</p> 12. The method of claim 1 or 7, wherein the level of the biomarker is determined by performing an ELISA.",
                            "source": "<p>Source:</p> US7919264B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Responsiveness",
                            "color": "teal",
                            "claimReason": "“… method for monitoring responsiveness of a subject …”",
                            "indClaim": "<p>[IC]</p> 1. A method for monitoring responsiveness of a subject to treatment with an inhibitor of complement C5, the method comprising: determining the concentration of at least two aHUSassociated biomarker proteins in a biological fluid obtained from the subject, wherein: <p>(a)</p> the aHUS-associated biomarker proteins are selected from the group consisting of TNFR1, MCP-1, TNFR1, IFN-, IL-6, a proteolytic fragment of complement component factor B, soluble C5b9 (sC5b9), prothrombin fragment F1+2, D-dimer, thrombomodulin, VCAM-1, von Willebrand Factor (vWF), complement component C5a, 2 microglobulin (2M), clusterin, cystatin C, NAG, TIMP-1, NGAL, fatty acid binding protein 1 (FABP-1), albumin, CXCL9, KIM-1, and CCL5, soluble CD40 ligand (sCD40L), ICAM-1, IL-1 beta, IL-12 p70, IL-8, and vascular endothelial cell growth factor (VEGF); <p>(b)</p> the subject has, is suspected of having, or is at risk for developing aHUS; <p>(c)</p> the subject has been or is being treated with an inhibitor of complement C5; and <p>(d)</p> the subject has a reduced concentration of the at least two aHUS biomarker proteins compared to the concentration measured in a sample of biological fluid of the same type obtained from the subject prior to treatment with the complement C5 inhibitor.",
                            "depClaim": "<p>[DC]</p> 2. The method of 1, wherein the complement C5 inhibitor is selected from the group consisting of a small molecule, a polypeptide, a polypeptide analog, a peptidomimetic, and an aptamer.<p>[DC]</p> 3. The method of 1, wherein the complement C5 inhibitor is selected from the group consisting of MB12/22, MB12/22-RGD, ARC187, ARC1905, SSL7, and OmCI.<p>[DC]</p> 4. The method of claim 1, wherein the complement C5 inhibitor is an antibody, or an antigenbinding fragment thereof.<p>[DC]</p> 5. The method of claim 4, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a humanized antibody, a recombinant antibody, a diabody, a chimerized or chimeric antibody, a monoclonal antibody, a deimmunized antibody, a fully human antibody, a single chain antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab fragment, and an F(ab)2 fragment.<p>[DC]</p> 6. The method of claim 4, wherein the antibody, or antigen-binding fragment thereof, binds to complement component C5 and inhibits cleavage of C5 into fragments C5a and C5b.<p>[DC]</p> 7. The method of claim 6, wherein the antibody is eculizumab or a variant of eculizumab.<p>[DC]</p> 8. The method of claim 6, wherein the antigen-binding fragment is pexelizumab.<p>[DC]</p> 9. The method of claim 1, wherein at least one of the aHUS-associated biomarkers is selected from the group consisting of: a proteolytic fragment Ba of factor B, TNFR1, VCAM-1, D-dimer, thrombomodulin, and cystatin C.",
                            "source": "<p>Source:</p> US9658236B2, Alexion Pharma. Company: Soliris® Product"
                        },
                        {
                            "name": "Monitoring of XYZ",
                            "color": "teal",
                            "claimReason": "“… method of monitoring an autoimmune disorder …”",
                            "indClaim": "<p>[IC]</p> 37. A method of monitoring an autoimmune disorder in a subject having the autoimmune disorder, the method comprising: assaying the subject for expression of one or more biomarkers following treatment with a TNF inhibitor, wherein the one or more biomarkers is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:29, 91, and 176, thereby monitoring the autoimmune disorder in the subject.",
                            "depClaim": "<p>[DC]</p> 38. The method of claim 37, further comprising monitoring the subject prior to treatment with a TNF inhibitor.<p>[DC]</p> 39. The method of claim 37, wherein a sample from the subject is assayed for protein expression of the one or more biomarkers.<p>[DC]</p> 40. The method of claim 37, wherein the subject is a human.<p>[DC]</p> 41. The method of claim 37, wherein the autoimmune disorder is rheumatoid arthritis.<p>[DC]</p> 42. The method of claim 37, wherein a sample from the subject is assayed for expression of an mRNA encoding the one or more biomarkers.",
                            "source": "<p>Source:</p> US8092998B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Safety",
                            "color": "teal",
                            "claimReason": "“… method for ameliorating or preventing an adverse effect mediated by the administration of a CD19×CD3 bispecific antibody …”",
                            "indClaim": "<p>[IC]</p> 32. A method for ameliorating or preventing an adverse effect mediated by the administration of a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, said method comprising: <p>(a)</p> determining the ratio of total B cells to total T cells in a peripheral blood sample from said human patient to identify patients at risk of developing an adverse effect; <p>(b)</p> identifying said human patient as having an increased risk of potential adverse effects when the ratio of B:T cells is about 1:5 or less before treatment; <p>(c)</p> administering a first dose of said antibody for a first period of time to said patient identified in <p>(d)</p>, and consecutively; <p>(e)</p> administering a second dose of said antibody for a second period of time; wherein said second dose exceeds said first dose, and wherein said CD19×CD3 bispecific antibody is MT103 (Blinatumomab).",
                            "depClaim": "<p>[DC]</p> 33. The method of claim 32, wherein said adverse effect is characterized by a neurological reaction.<p>[DC]</p> 34. The method of claim 33, wherein said neurological reaction is one or more selected from the group consisting of: confusion, ataxia, disorientation, dysphasia, aphasia, speech impairment, cerebellar symptoms, tremor, apraxia, seizure, grand mal convulsion, palsy, and balance disorder.",
                            "source": "<p>Source:</p> US8840888B2, Amgen Company: Blincyto® Product"
                        }
                    ]
                },
                {
                    "name": "Production",
                    "color": "teal",
                    "children": [
                        {
                            "name": "General Method",
                            "color": "teal",
                            "claimReason": "“… method for producing a host cell protein (HCP)-reduced antibody preparation …”",
                            "indClaim": "<p>[IC]</p> 1. A method for producing a host cell protein (HCP)-reduced antibody preparation from a mixture comprising an antibody and at least one HCP, the method comprising: applying the mixture to a cation exchange resin equilibrated with an equilibration buffer, wherein greater than 30 grams of antibody per liter of cation exchange resin are applied; washing HCP from the cation exchange resin with a plurality of wash steps comprising a first wash and a second wash, wherein conductivity of the first wash is equivalent to conductivity of the equilibration buffer and there is an increase in conductivity with each successive wash in the plurality of wash steps; eluting the antibody from the cation exchange resin with an elution buffer to form a first eluate; applying the first eluate to an anion exchange resin, wherein prior to applying the first eluate to the anion exchange resin, pH and conductivity of the first eluate are adjusted to be substantially similar to pH and conductivity of the anion exchange resin; obtaining a first flowthrough comprising the antibody, and obtaining the HCP-reduced antibody preparation therefrom.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein about 35-70 grams of antibody per liter of cation exchange resin are applied.<p>[DC]</p> 3. The method of claim 1, wherein the cation exchange resin is at pH 5 and about 70 grams of antibody per liter of resin are applied.<p>[DC]</p> 4. The method of claim 1, wherein the mixture comprising an antibody and at least one HCP is not subjected to protein A capture prior to applying the mixture to the cation exchange resin.<p>[DC]</p> 5. The method of claim 1, wherein the first wash is with equilibration buffer and the second wash is with a mixture of elution buffer and water.<p>[DC]</p> 6. The method of claim 5, wherein the mixture of elution buffer and water comprises about 40-50% elution buffer and about 50-60% water.<p>[DC]</p> 7. The method of claim 6, wherein the mixture of elution buffer and water comprises about 45% elution buffer and about 55% water.<p>[DC]</p> 8. The method of claim 7, wherein the elution buffer comprises 20 mM sodium phosphate and 150 mM sodium chloride.<p>[DC]</p> 9. The method of claim 1, which carried wherein the cation exchange resin is at pH 7.<p>[DC]</p> 10. The method of claim 1, wherein the cation exchange resin is at a pH between about pH 5 and about pH 7.<p>[DC]</p> 11. The method of claim 1, wherein the cation exchange resin is at a pH of 5.<p>[DC]</p> 12. The method of claim 1, wherein the cation exchange resin is formed into a column and the mixture comprising the antibody and at least one HCP is applied to the column.<p>[DC]</p> 13. The method of claim 12, wherein the cation exchange resin comprises a synthetic methacrylate based polymeric resin attached to a sulfonate group.<p>[DC]</p> 14. The method of claim 1, which further comprises subjecting the first eluate to a viral inactivation step.<p>[DC]</p> 15. The method of claim 14, wherein viral inactivation is achieved by pH viral inactivation such that the first eluate is virally inactivated.<p>[DC]</p> 16. The method of claim 1, wherein the pH of the anion exchange resin is in a range of about pH 7.7 to about pH 8.3 and the pH of the first eluate is adjusted to be in a range of about pH 7.7 to about pH 8.3.<p>[DC]</p> 17. The method of claim 16, wherein the pH of the anion exchange resin is about pH 8.0 and the pH of the first eluate is adjusted to be about pH 8.0.<p>[DC]</p> 18. The method of claim 1, wherein the conductivity of the anion exchange resin is in a range of about 3.5 mS/cm to about 5.2 mS/cm and the conductivity of the first eluate is adjusted to be in a range of about 3.5 mS/cm to about 5.2 mS/cm.<p>[DC]</p> 19. The method of claim 18, wherein the conductivity of the anion exchange resin is about 5.0 mS/cm and the conductivity of the first eluate is adjusted to be about 5.0 mS/cm.<p>[DC]</p> 20. The method of claim 1, wherein the anion exchange resin is a Q sepharose resin.<p>[DC]</p> 21. The method of claim 1, wherein the anion exchange resin is formed into a column.<p>[DC]</p> 22. The method of claim 1, further comprising applying the first flow through to a hydrophobic interaction column such that a second eluate is obtained.<p>[DC]</p> 23. The method of claim 22, wherein the hydrophobic interaction column is a phenyl sepharose column.<p>[DC]</p> 24. The method of claim 22, wherein the first flow through comprises about 20 to about 40 grams of antibody per liter of hydrophobic interaction column material.<p>[DC]</p> 25. The method of claim 24, wherein the first flow through comprises about 30 to about 36 grams of antibody per liter of hydrophobic interaction column material.<p>[DC]</p> 26. The method of claim 22, wherein the second eluate is not subjected to product peak fractionation.<p>[DC]</p> 27. The method of claim 1, wherein the HCP comprises procathepsin L such that a procathepsin L-reduced antibody preparation is obtained.<p>[DC]</p> 28. The method of claim 27, wherein the first eluate comprises cathepsin L activity ranging from between about 25 to about 60 RFU/s/mg of antibody as measured by a cathepsin L kinetic assay.<p>[DC]</p> 29. The method of claim 27, wherein the level of procathepsin L is reproducibly low.<p>[DC]</p> 30. The method of any one of claims 1-4, 5, 10, 11 or 14, wherein the antibody is an anti-tumor necrosis factor-alpha (TNF) antibody, or antigen-binding portion thereof.<p>[DC]</p> 31. The method of claim 30, wherein the anti-TNF antibody, or antigen binding portion thereof, is a humanized antibody, a chimeric antibody or a multivalent antibody.<p>[DC]</p> 32. The method of claim 30, wherein the anti-TNF antibody, or antigen binding portion thereof, is infliximab.<p>[DC]</p> 33. The method of claim 30, wherein the anti-TNF antibody, or antigen-binding portion thereof, is a human antibody.<p>[DC]</p> 34. The method of claim 33, wherein the anti-TNF antibody, or antigen-binding portion thereof, is an isolated human antibody that dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less.<p>[DC]</p> 35. The method of claim 33, wherein the anti-TNF antibody, or antigen-binding portion thereof, is an isolated human antibody with the following characteristics: <p>(a)<p> dissociates from human TNF with a K off rate constant of 1×103 s1 or less, as determined by surface plasmon resonance; <p>(b)</p> has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; <p>(c)</p> has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.<p>[DC]</p> 36. The method of claim 33, wherein the anti-TNF antibody, or antigen binding portion thereof, is an isolated human antibody with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.<p>[DC]</p> 37. The method of claim 33, wherein the anti-TNF antibody, or antigen binding portion thereof, is adalimumab.<p>[DC]</p> 38. The method of claim 30, wherein the anti-TNF antibody, or antigen binding portion thereof, is golimumab.",
                            "source": "<p>Source:</p> US7863426B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Batch Method",
                            "color": "teal",
                            "claimReason": "“… fed-batch production method of making a human anti-TNF antibody …”",
                            "indClaim": "<p>[IC]</p> 1. A fed-batch production method of making a human anti-TNF antibody which comprises <p>(a)</p> a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:1 and <p>(b)</p> a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, said method comprising culturing Chinese Hamster Ovary (CHO) cells comprising a nucleic acid encoding said anti-TNF antibody in a cell culture production medium in large-scale, wherein the glucose concentration in said medium is monitored, the glucose concentration in said medium decreases to below 2 g/L, and glucose is added to said medium when the glucose concentration in said medium decreases to below 2 g/L, or the glucose concentration in said medium is monitored and glucose is added to said medium to maintain the glucose concentration in said medium at a concentration of at least 2 g/L but no greater than 7 g/L, such that said anti-TNF antibody is produced at a titer of at least 2 g/L in said cell culture production medium.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein said anti-TNF antibody is produced at a titer of at least 2.5 g/L in said cell culture production medium.<p>[DC]</p> 3. The method of claim 1, wherein said anti-TNF antibody is produced at a titer of at least 4 g/L in said cell culture production medium.<p>[DC]</p> 4. The method of claim 1, wherein said culturing lasts 9-15 days.<p>[DC]</p> 5. The method of claim 1, wherein said cell culture production medium is a serum-free medium.<p>[DC]</p> 6. The method of claim 5, wherein said serum-free medium comprises at least one non-animalbased hydrolysate.<p>[DC]</p> 7. The method of claim 6, wherein said serum-free medium comprises a recombinant growth factor, an osmolarity regulator, a pH buffer agent, glutamine, methotrexate, and a cell protectant.<p>[DC]</p> 8. The method of claim 5, wherein said serum-free medium comprises galactose and manganese.<p>[DC]</p> 9. The method of claim 1, wherein said CHO cells are cultured at a temperature ranging from 32°C. to 38°C.<p>[DC]</p> 10. The method of claim 9, wherein said temperature is maintained as a constant temperature throughout said production method, said temperature being selected from a temperature range of 32°C. to 38°C.",
                            "source": "<p>Source:</p> US8911964B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Condition XYZ Specific",
                            "color": "teal",
                            "claimReason": "“… wherein the disorder is rheumatoid arthritis ... Crohn's disease ... ulcerative colitis. …”",
                            "indClaim": "<p>[IC]</p> 4. A method of treating a disorder in which TNF activity is detrimental in a subject, the method comprising administering a composition comprising a therapeutically effective amount of adalimumab to the subject such that the disorder is treated, wherein the adalimumab is produced in a Chinese Hamster Ovary (CHO) cell expression system; wherein the disorder is selected from the group consisting of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and juvenile rheumatoid arthritis; and wherein the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity from 0.4 to 0.9 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises: <p>(i)</p> diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5, <p>(ii)</p> adding dextran sulfate to a concentration of 0.035 g/mL and incubating at 37° C. for six hours, <p>(iii)</p> adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and <p>(iv)</p> measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.",
                            "depClaim": "<p>[DC]</p> 5. The method of claim 4, wherein the cathepsin L activity is from 0.4 to 0.6 RFU/s/mg of adalimumab.<p>[DC]</p> 6. The method of claim 4, wherein the cathepsin L activity is from 0.4 to 0.85 RFU/s/mg of adalimumab.<p>[DC]</p> 7. The method of any one of claims 1 and 2-6, wherein the composition is packaged in a pre-filled syringe.<p>[DC]</p> 8. The method of any one of claims 1 and 2-6, wherein the composition comprises 50 mg/ml of adalimumab.<p>[DC]</p> 9. The method of any one of claims 1 and 2-6, wherein the composition is suitable for subcutaneous injection.<p>[DC]</p> 10. The method of any one of claims 1 and 2-6, wherein the diluted composition has an adalimumab concentration of 20 g/ml.<p>[DC]</p> 11. The method of any one of claims 1 and 2-6, wherein the diluted composition has an adalimumab concentration of 50 g/ml.<p>[DC]</p> 12. The method of any one of claims 1 and 2-6, wherein step i) of the cathepsin L kinetic assay comprises diluting the composition 600 fold.<p>[DC]</p> 13. The method of claim 4, wherein the disorder is rheumatoid arthritis.<p>[DC]</p> 14. The method of claim 4, wherein the disorder is Crohn's disease.<p>[DC]</p> 15. The method of claim 4, wherein the disorder is ulcerative colitis.<p>[DC]</p> 16. The method of claim 4, wherein the disorder is ankylosing spondylitis.<p>[DC]</p> 17. The method of claim 4, wherein the disorder is psoriatic arthritis.<p>[DC]</p> 18. The method of claim 4, wherein the disorder is psoriasis.<p>[DC]</p> 19. The method of claim 4, wherein the disorder is juvenile rheumatoid arthritis.",
                            "source": "<p>Source:</p> US8906372B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Concentrating",
                            "color": "teal",
                            "claimReason": "“… method for concentrating an immunoglobulin solution by tangential flow filtration …”",
                            "indClaim": "<p>[IC]</p> 1. A method for concentrating an immunoglobulin solution by tangential flow filtration, characterized in that the transmembrane pressure and the cross-flow are variable, and changed during the filtration process according to the concentration of the immunoglobulin to be concentrated, wherein <p>(i)</p> a transmembrane pressure of from 1.4 bar to 1.6 bar and a cross-flow of from 75 ml/min. to 90 ml/min. is applied in a concentration range up to 30 mg immunoglobulin per ml of solution to be concentrated, <p>(ii)</p> a transmembrane pressure of from 0.8 bar to 0.9 bar and a cross-flow of from 140 ml/min. to 160 ml/min. is applied in a concentration range of from 15 mg/ml up to 55 mg/ml, and <p>(iii)</p> a transmembrane pressure of from 0.8 bar to 0.9 bar and a cross-flow of from 120 ml/min. to 140 ml/min is applied in a concentration range of more than 45 mg/ml up to about 130 mg/ml.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the transmembrane pressure and cross-flow in <p>(i)</p> are 1.5 bar and 80 ml/min., in <p>(ii)</p> are 0.85 bar and 150 ml/min., and; in <p>(iii)</p> are 0.85 bar and 130 ml/min.<p>[DC]</p> 3. The method of claim 1, wherein the concentration range is in <p>(i)</p> of 5 to 25 mg/ml, in <p>(ii)</p> of from 25 to 50 mg/ml, and in <p>(iii)</p> from 50 to 140 mg/ml.",
                            "source": "<p>Source:</p> US8633302B2, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Disulfide bond",
                            "color": "teal",
                            "claimReason": "“… method for the prevention of the reduction of a disulfide bond in an antibody expressed in a recombinant host cell …”",
                            "indClaim": "<p>[IC]</p> 1. A method for the prevention of the reduction of a disulfide bond in an antibody expressed in a recombinant host cell, comprising, following fermentation, sparging the pre-harvest or harvested culture fluid of said recombinant host cell with air, wherein the amount of dissolved oxygen (dO2) in the pre-harvest or harvested culture fluid is at least 10%.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1 wherein said air sparging is continued until the pre-harvest or harvested culture fluid is at least 30% saturated with air.<p>[DC]</p> 3. The method of claim 1 wherein said air sparging is continued until the pre-harvest or harvested culture fluid is between about 100% saturated to about 30% saturated with air.<p>[DC]</p> 4. The method of claim 1 wherein the amount of dissolved oxygen (dO2) in the pre-harvest or harvested culture fluid is at least 30%.<p>[DC]</p> 5. The method of claim 1 wherein the antibody is a therapeutic antibody.<p>[DC]</p> 6. The method of claim 1 wherein the antibody is a biologically functional fragment of an antibody.<p>[DC]</p> 7. The method of claim 1 wherein the host cell is eukaryotic host cell.<p>[DC]</p> 8. The method of claim 7 wherein the eukaryotic host cell is a mammalian host cell.<p>[DC]</p> 9. The method of claim 1 wherein the host cell is prokaryotic host cell.<p>[DC]</p> 10. The method of claim 9 wherein the prokaryotic host cell is a bacterial cell.",
                            "source": "<p>Source:</p> US8574869B2, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Humanisation",
                            "color": "teal",
                            "claimReason": "“… method for making a humanized antibody … comprising the steps of …”",
                            "indClaim": "<p>[IC]</p> 1. A method for making a humanized antibody comprising non-human, import Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, comprising the steps of: <p>(a)</p> obtaining the amino acid sequences of an import variable domain and of a VH subgroup III consensus human variable domain; <p>(b)</p> identifying CDR amino acid sequences in the import and the human variable domain sequences; <p>(c)</p> substituting import CDRs for the corresponding human CDRs; <p>(d)</p> aligning the amino acid sequences of a FR of the import antibody and the corresponding FR of the consensus variable domain; <p>(e)</p> identifying import antibody FR residues in the aligned FR sequences that are nonhomologous to the corresponding consensus variable domain residues; <p>(f)</p> determining if the non-homologous import amino acid residue is expected to have at least one of the following effects: <p>(1)</p> non-covalently binds antigen directly; <p>(2)</p> interacts with a CDR; or <p>(3)</p> participates in the VL -VH interface; <p>(g)</p> for any non-homologous import antibody amino acid residue which is expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus variable domain FR sequence; and <p>(h)</p> preparing a humanized antibody which binds antigen, wherein the humanized antibody.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, having an additional step of determining if any such non-homologous residues are exposed on the surface of the domain or buried within it, and if the residue is exposed, retaining the consensus residue.<p>[DC]</p> 3. The method of claim 1, having the additional steps of searching the import variable domain sequence for glycosylation sites, determining if any such glycosylation site is expected to affect the antigen binding or affinity of the antibody, and if so, substituting the glycosylation site into the consensus sequence.<p>[DC]</p> 4. The method of claim 1, having the additional steps of searching the consensus variable domain sequence for glycosylation sites which are not present at the corresponding amino acid in the import sequence, and if the glycosylation site is not present in the import sequence, substituting the import amino acid residues for the amino acid residues comprising the consensus glycosylation site.<p>[DC]</p> 5. The method of claim 1, having an additional step which comprises aligning import antibody and consensus variable domain FR sequences, identifying import antibody FR residues which are nonhomologous with the aligned consensus FR sequence, and for each such non-homologous import antibody FR residue, determining if the corresponding consensus variable domain residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus amino acid residue at that site.<p>[DC]</p> 6. The method of claim 1, wherein the corresponding consensus residues are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91H, 92H, 93H, and 103H.",
                            "source": "<p>Source:</p> US6054297A, Genentech Company: Lucentis® Product"
                        }
                    ]
                },
                {
                    "name": "Modification",
                    "color": "teal",
                    "children": [
                        {
                            "name": "Reducing Impurities",
                            "color": "teal",
                            "claimReason": "“… A method for producing a preparation comprising a protein of interest and having a reduced level of at least one impurity …”",
                            "indClaim": "<p>[IC]</p> 1. A method for producing a preparation comprising a protein of interest and having a reduced level of at least one impurity, said method comprising: <p>(a)</p> contacting a sample comprising the protein of interest and at least one impurity, to a hydrophobic interaction chromatography (HIC) media, in the presence of a load buffer such that <p>(i)</p> a portion of the protein of interest binds to the HIC media at a Kp of greater than 20 and <p>(ii)</p> a substantial portion of the at least one impurity binds to the HIC media; <p>(b)</p> collecting a flow through fraction comprising the protein of interest unbound to the HIC media; <p>(c)</p> washing the HIC media with a wash buffer such that a substantial portion of the protein of interest bound to the HIC media is released from the media, wherein the salt concentration and/or the pH of the wash buffer are within 20% of the salt concentration and/or pH of the load buffer; and <p>(d)</p> collecting a wash fraction comprising the protein of interest released from the HIC media, wherein each of the flow through and wash fractions comprise the protein of interest and have a reduced level of the at least one impurity.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the protein of interest is an antibody or antigen-binding fragment thereof, a soluble protein, a membrane protein, a structural protein, a ribosomal protein, an enzyme, a zymogen, an antibody molecule, a humanized antibody or antigen-binding portion thereof, a human antibody or antigen-binding portion thereof, a chimeric antibody or antigenbinding portion thereof, a multivalent antibody, a cell surface receptor protein, a transcription regulatory protein, a translation regulatory protein, a chromatin protein, a hormone, a cell cycle regulatory protein, a 0 protein, a neuroactive peptide, an immunoregulatory protein, a blood component protein, an ion gate protein, a heat shock protein, an antibiotic resistance protein, a functional fragment of any of the preceding proteins, an epitope-containing fragment of any of the preceding proteins, and combinations thereof.<p>[DC]</p> 3. The method of claim 1, wherein the portion of the protein of interest binds to the HIC media at a Kp of greater than 50.<p>[DC]</p> 4. The method of claim 1, wherein the portion of the protein of interest binds to the HIC media at a Kp of greater than 100.<p>[DC]</p> 5. The method of claim 1, wherein the portion of the protein of interest binds to the HIC media at a Kp of greater than 200.<p>[DC]</p> 6. A method for producing a preparation comprising adalimumab and having a reduced level of at least one impurity, said method comprising: <p>(a)</p> contacting a sample comprising adalimumab and at least one impurity, to a HIC media, in the presence of a load buffer such that <p>(i)</p> a portion of the adalimumab in the sample binds to the HIC media at a Kp of greater than 20 and <p>(ii)</p> a substantial portion of the at least one impurity binds to the HIC media; <p>(b)</p> collecting a flow through fraction comprising the adalimumab unbound to the HIC media; <p>(c)</p> washing the HIC media with a wash buffer such that a substantial portion of the adalimumab bound to the HIC media is released from the media, wherein the salt concentration and/or the pH of the wash buffer are within 20% of the salt concentration and/or pH of the load buffer; and <p>(d)</p> collecting a wash fraction comprising the adalimumab released from the HIC media, wherein each of the flow through and wash fractions comprise adalimumab and have a reduced level of the at least one impurity.<p>[DC]</p> 7. The method of claim 6, wherein a substantial portion of the impurity bound to the HIC media remains bound upon washing with the wash buffer.<p>[DC]</p> 8. The method of claim 6, wherein the flow through and/or wash fractions are substantially free of the at least one impurity.<p>[DC]</p> 9. The method of claim 6, wherein the at least one impurity is an aggregate of the protein of interest.",
                            "source": "<p>Source:</p> US8946395B1, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Purificiation",
                            "color": "teal",
                            "children": [
                                {
                                    "name": "Assay for determining functionality",
                                    "color": "teal",
                                    "claimReason": "“…  the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.84 RFU/s/mg of adalimumab is observed …”",
                                    "indClaim": "<p>[IC]</p> 1. A liquid composition comprising adalimumab, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.84 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises: <p>(i)</p> diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5, <p>(ii)</p> adding dextran sulfate to a concentration of 0.035 g/mL and incubating at 37° C. for six hours, <p>(iii)</p> adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and <p>(iv)</p> measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.",
                                    "depClaim": "<p>[DC]</p> 2. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 1.3 RFU/s/mg of adalimumab.<p>[DC]</p> 3. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 1.0 RFU/s/mg of adalimumab.<p>[DC]</p> 4. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 0.6 RFU/s/mg of adalimumab.<p>[DC]</p> 5. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 0.85 RFU/s/mg of adalimumab.<p>[DC]</p> 6. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 0.9 RFU/s/mg of adalimumab.<p>[DC]</p> 7. The liquid composition of claim 1, wherein the composition is packaged in a pre-filled syringe.<p>[DC]</p> 8. The liquid composition of claim 1, wherein the composition comprises 50 mg/ml of adalimumab.<p>[DC]</p> 9. The liquid composition of claim 1, wherein the composition is suitable for subcutaneous injection.<p>[DC]</p> 10. The liquid composition of claim 1, wherein the diluted composition has an adalimumab concentration of 20 g/ml.<p>[DC]</p> 11. The liquid composition of claim 1, wherein the diluted composition has an adalimumab concentration of 50 g/ml.<p>[DC]</p> 12. The liquid composition of claim 1, wherein step <p>(i)</p> of the cathepsin L kinetic assay comprises diluting the composition 600 fold.",
                                    "source": "<p>Source:</p> US9096666B2, Abott Biotech Company: Humira® Product"
                                },
                                {
                                    "name": "Various Methodologies",
                                    "color": "teal",
                                    "claimReason": "“… process for purifying adalimumab from a fermentation harvest of a Chinese Hamster Ovary …”",
                                    "indClaim": "<p>[IC]</p> 1. A process for purifying adalimumab from a fermentation harvest of a Chinese Hamster Ovary (CHO) cell culture expressing said adalimumab, said process comprising: <p>(a)</p> binding adalimumab from said fermentation harvest to a Protein A resin, <p>(b)</p> eluting the bound adalimumab at an elution pH of 3.6-4, and <p>(c)</p> incubating the eluted adalimumab for 1 to 3 hours.",
                                    "depClaim": "<p>[DC]</p> 2. The process of claim 1, wherein said eluting is at an elution pH is 3.6.<p>[DC]</p> 3. The process of claim 1, wherein said eluting is at an elution pH of 3.7.<p>[DC]</p> 4. The process of claim 1, wherein said eluting is at an elution pH of 3.8.<p>[DC]</p> 5. The process of claim 1, wherein said eluting is at an elution pH of 4.<p>[DC]</p> 6. The process of claim 1, further comprising after said incubating, subjecting adalimumab to one or more further chromatographic separations, wherein said one or more further chromatographic separations comprise an ion exchange chromatography, a hydrophobic interactive chromatography or a combination thereof.<p>[DC]</p> 7. The process of claim 1, further comprising subjecting adalimumab to an ion exchange chromatography after said incubating.<p>[DC]</p> 8. The process of claim 7, wherein said ion exchange chromatography is cation exchange chromatography.<p>[DC]</p> 9. The process of claim 7, wherein said ion exchange chromatography is anion exchange chromatography.<p>[DC]</p> 10. The process of claim 1, further comprising subjecting adalimumab to a hydrophobic interaction chromatography after said incubating.<p>[DC]</p> 11. The process of claim 1, further comprising determining the monomer level of adalimumab purified according to said process.<p>[DC]</p> 12. The process of claim 1, wherein the adalimumab monomer level after said incubating is greater than 97%.<p>[DC]</p> 13. The process of claim 1, wherein the purified adalimumab is pharmaceutical grade.",
                                    "source": "<p>Source:</p> US9018361B2, Abott Biotech Company: Humira® Product"
                                }
                            ]
                        },
                        {
                            "name": "Galactosylation",
                            "color": "teal",
                            "claimReason": "“… method for modifying the glycosylation profile of a polypeptide …”",
                            "indClaim": "<p>[IC]</p> 2. A method for modifying the glycosylation profile of a polypeptide produced by a mammalian host cell, comprising introducing into said host cell an expression vector which comprises an isolated nucleic acid comprising a sequence encoding a fusion polypeptide, wherein said fusion polypeptide has (1,4)-N-acetylglucosaminyltransferase III activity and comprises the Golgi localization domain of mannosidase II, and wherein said modified polypeptide has increased Fcreceptor binding or effector function as a result of said modification.",
                            "depClaim": "<p>[DC]</p> 3. A method according to claim 1 or 2, wherein said polypeptide is IgG or a fragment thereof.<p>[DC]</p> 4. A method according to claim 3, wherein said polypeptide is IgG1 or a fragment thereof.<p>[DC]</p> 5. A method according to claim 3, wherein said polypeptide is a fusion protein that includes a region equivalent to the Fc region of a human IgG.",
                            "source": "<p>Source:</p> US8367374B2, Roche Company: Gazyva® Product"
                        },
                        {
                            "name": "PH",
                            "color": "teal",
                            "claimReason": "“… comprising formulating the antibody in an arginine acetate buffer, pH 4.5 to 6.0 …”",
                            "indClaim": "<p>[IC]</p> 2. A method for reducing aggregation of a therapeutic monoclonal antibody, comprising formulating the antibody in an arginine acetate buffer, pH 4.5 to 6.0, wherein the antibody is bevacizumab.",
                            "depClaim": "<p>[DC]</p> 3. The method of claim 2, wherein the buffer is an arginine acetate buffer, pH 4.5 to 5.5.<p>[DC]</p> 4. The method of claim 2, wherein the buffer is an arginine acetate buffer, pH 4.8 to 5.4.<p>[DC]</p> 5. The method of claim 2, wherein the buffer is an arginine acetate buffer, pH 5.2.<p>[DC]</p> 6. The method of claim 3, wherein the arginine actetate concentration in the buffer is from about 25 mM to about 250 mM.<p>[DC]</p> 7. The method of claim 3, wherein the arginine actetate concentration in the buffer is from about 50 mM to about 250 mM.<p>[DC]</p> 8. The method of claim 3, wherein the arginine actetate concentration in the buffer is from about 75 mM to about 250 mM.<p>[DC]</p> 9. The method of claim 3, wherein the arginine actetate concentration in the buffer is from about 100 mM to about 250 mM.<p>[DC]</p> 10. The method of claim 3, wherein the arginine acetate concentration in the buffer is from about 120 mM to about 240 mM.<p>[DC]</p> 11. The method of claim 3, wherein arginine acetate concentration in the buffer is from about 150 mM to about 225 mM.<p>[DC]</p> 12. The method of claim 3, wherein the arginine acetate concentration in the buffer is about 200 mM.<p>[DC]</p> 13. The method of claim 2, wherein the formulation further comprises a surfactant.<p>[DC]</p> 14. The method of claim 13, wherein the surfactant is polysorbate.<p>[DC]</p> 15. The method of claim 14, wherein the polysorbate is polysorbate 20.<p>[DC]</p> 16. The method of claim 13, wherein the surfactant concentration is from 0.0001% to about 1.0%.<p>[DC]</p> 17. The method of claim 13, wherein the surfactant concentration is from about 0.01% to about 0.05%.<p>[DC]</p> 18. The method of claim 13, wherein the surfactant concentration is 0.04%.<p>[DC]</p> 19. The method of claim 2, wherein the antibody concentration is from about 10 mg/ml to about 250 mg/ml.<p>[DC]</p> 20. The method of claim 2, wherein the antibody concentration is from about 25 mg/ml to 200 mg/ml.<p>[DC]</p> 21. The method of claim 2, wherein the antibody concentration is from about 50 mg/ml to about 150 mg/ml.<p>[DC]</p> 22. The method of claim 2, wherein the antibody concentration is from about 75 mg/ml to about 125 mg/ml.<p>[DC]</p> 23. The method of claim 2, wherein the antibody is not subject to prior lyophilization.",
                            "source": "<p>Source:</p> US9226961B2, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Viscosity",
                            "color": "teal",
                            "claimReason": "“… method of reducing the viscosity to about 50 cs or less of a subcutaneous formulation …”",
                            "indClaim": "<p>[IC]</p> 1. A method of reducing the viscosity to about 50 cs or less of a subcutaneous formulation containing 100 mg/ml of a monoclonal antibody comprising the addition of a salt in an amount greater than 100 mM, wherein the salt is selected from the group consisting of arginine hydrochloride, sodium thiocyanate, ammonium thiocyanate, ammonium sulfate, ammonium chloride, calcium chloride, zinc chloride and sodium acetate.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1 wherein said salt is added in an amount greater than 100 to about 200 mM.<p>[DC]</p> 3. The method of claim 2 wherein the amount of added salt is about 200 mM.<p>[DC]</p> 4. The method of claim 1 wherein said antibody is directed against IgE.<p>[DC]</p> 5. The method of claim 4 wherein the antibody is rhuMAb-E25.<p>[DC]</p> 6. The method of claim 4, wherein the antibody is rhuMAb-E26.<p>[DC]</p> 7. The method of claim 4, wherein the antibody is rhuMAb-E27.<p>[DC]</p> 8. The method of claim 1 wherein said formulation is a reconstituted lyophilized formulation.<p>[DC]</p> 9. The method of claim 8 wherein the protein concentration in said reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.<p>[DC]</p> 10. The method of claim 1 wherein the formulation is hypertonic.<p>[DC]</p> 11. The method of claim 1, wherein the viscosity is about 40 cs or less.<p>[DC]</p> 12. The method of claim 1, wherein the viscosity is about 30 cs or less.<p>[DC]</p> 13. The method of claim 1, wherein the viscosity is about 20 cs or less.<p>[DC]</p> 14. The method of claim 1, wherein the viscosity is about 10 to 30 cs.<p>[DC]</p> 15. The method of claim 1, wherein the added salt is arginine hydrochloride.<p>[DC]</p> 16. The method of claim 1, wherein the added salt is sodium thiocyanate.<p>[DC]</p> 17. The method of claim 1, wherein the added salt is ammonium thiocyanate.<p>[DC]</p> 18. The method of claim 1, wherein the added salt is ammonium sulfate.<p>[DC]</p> 19. The method of claim 1, wherein the added salt is ammonium chloride.<p>[DC]</p> 20. The method of claim 1, wherein the added salt is calcium chloride.<p>[DC]</p> 21. The method of claim 1, wherein the added salt is sodium acetate.",
                            "source": "<p>Source:</p> US7666413B2, Genentech Company: Xolair® Product"
                        }
                    ]
                },
                {
                    "name": "Host Cells",
                    "color": "teal",
                    "children": [
                        {
                            "name": "Enhancing Protein Expression",
                            "color": "teal",
                            "claimReason": "“… method of improving or enhancing the ability of a population of host cells that express a recombinant protein …”",
                            "indClaim": "<p>[IC]</p> 32. A method of improving or enhancing the ability of a population of host cells that express a recombinant protein to adapt to growth in the presence of methotrexate comprising the step of: inserting into host cells a recombinant expression vector comprising: a recombinant gene encoding a recombinant protein of interest, a recombinant expression vector element (rEVE) polynucleotide molecule comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, a portion of SEQ ID NO:1, a portion of SEQ ID NO:2, and combinations thereof, and a dihydrofolate reductase (DHFR) gene; wherein a population of the host cells containing the recombinant expression vector has a higher survivability and/or higher growth rate when grown in the presence of methotrexate compared to a population of host cells carrying the same recombinant expression vector lacking the rEVE polynucleotide molecule.",
                            "depClaim": "<p>[DC]</p> 33. The method according to claim 32, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 M.<p>[DC]</p> 34. The method according to claim 32, wherein said host cell is a CHO host cell.",
                            "source": "<p>Source:</p> US7935808B2, Abott Biotech Company: Humira® Product"
                        },
                        {
                            "name": "Prolonging Viability",
                            "color": "teal",
                            "claimReason": "“… A method of prolonging host cell viability in a cell culture …”",
                            "indClaim": "<p>[IC]</p> 21. A method of prolonging host cell viability in a cell culture, comprising the steps of: <p>(a)</p> providing a vector comprising a gene encoding caspase-9 dominant negative protein, <p>(b)</p> providing a vector comprising a gene encoding a protein of interest, <p>(c)</p> providing a Chinese hamster ovary (CHO) host cell, <p>(d)</p> transforming or transfecting the host cell with the vector of steps (a) and (b), <p>(e)</p> providing cell culture media, <p>(f)</p> culturing the transformed or transfected host cell in the cell culture media under conditions sufficient for expression of the protein of interest and an amount of caspase-9 dominant negative protein which is effective for prolonging viability of the host cells in the cell culture, and optionally <p>(g)</p> recovering or purifying the protein of interest from the host cell and/or the cell culture media.",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US6586206B1, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Reducing Production of Undesirable XYZ",
                            "color": "teal",
                            "claimReason": "“… method for reducing lactate production in cultured cells …”",
                            "indClaim": "<p>[IC]</p> 1. A method for reducing lactate production in cultured cells, the method comprising culturing cells comprising a first heterologous nucleic acid sequence encoding a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and a second heterologous nucleic acid sequence encoding an siRNA specific for a pyruvate dehydrogenase kinase (PDHK), wherein the first heterologous nucleic acid sequence is operably linked to a first promoter, and wherein the second heterologous nucleic acid sequence is operably linked to a second promoter, wherein the cultured cells have a polypeptide productivity of at least about 68% higher than cultured cells without the heterologous nucleic acid sequence comprising siRNA specific for PDHK and the siRNA specific for LDH.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the LDH is LDHa.<p>[DC]</p> 3. The method of claim 1, wherein the cultured cells further comprise a third heterologous nucleic acid sequence encoding an siRNA specific for a second PDHK and wherein the third heterologous nucleic acid sequence is operably linked to a third promoter.<p>[DC]</p> 4. The method of claim 3, wherein the cultured cells further comprise a fourth heterologous nucleic acid sequence encoding an siRNA specific for a third PDHK and wherein the fourth heterologous nucleic acid sequence is operably linked to a fourth promoter.<p>[DC]</p> 5. The method of claim 4, wherein cultured cells further comprise a fifth heterologous nucleic acid sequence encoding an siRNA specific for a fourth PDHK and wherein the fifth heterologous nucleic acid sequence is operably linked to a fifth promoter.<p>[DC]</p> 6. The method of any one of claims 1, 3, 4, and 5, wherein the PDHK is selected from the group consisting of PDHK1, PDHK2, PDHK3, and PDHK4.<p>[DC]</p> 7. The method of claim 1, wherein the cultured cells produce a heterologous polypeptide.<p>[DC]</p> 8. The method of claim 7, wherein the heterologous polypeptide is an antibody.<p>[DC]</p> 9. The method of claim 4, wherein an average lactate production rate of the cultured cells is less than about negative 0.02 mg/106 cells/day.<p>[DC]</p> 10. The method of claim 4, wherein the cultured cells have a Specific Productivity of at least about 75% higher than cultured cells without the heterologous nucleic acid sequence comprising the siRNA specific for PDHKs and the siRNA specific for LDH.<p>[DC]</p> 11. The method of claim 4, wherein the cultured cells maintain an osmolality at less than about 300 mOsm over 14 days.<p>[DC]</p> 12. The method of claim 7, wherein the cultured cells are mammalian cells.",
                            "source": "<p>Source:</p> US9487809B2, Genentech Company: Avastin® Product"
                        },
                        {
                            "name": "Reducing Consumption of XYZ",
                            "color": "teal",
                            "claimReason": "“… method for reducing glucose consumption during cultivation of CHO, myeloma, or hybridoma cells …”",
                            "indClaim": "<p>[IC]</p> 1. A method for reducing glucose consumption during cultivation of CHO, myeloma, or hybridoma cells, comprising cultivating CHO, myeloma, or hybridoma cells in culture medium in the presence of citric acid or citrate wherein said citric acid or citrate is maintained at a concentration of about 1 to 50 mmol/l during cultivation and wherein said citric acid or citrate is not bound in a chelate complex with iron or another transition metal ion.",
                            "depClaim": "<p>[DC]</p> 2. The method of claim 1, wherein the cells are myeloma cells.<p>[DC]</p> 3. The method of claim 1, wherein the cells are hybridoma or CHO cells.",
                            "source": "<p>Source:</p> US7390660B2, Genentech Company: Herceptin® Product"
                        },
                        {
                            "name": "Capable of Producing XYZ",
                            "color": "teal",
                            "claimReason": "“… hybridoma capable of producing an antibody that is capable of reacting specifically with …”",
                            "indClaim": "<p>[IC]</p> 1. A hybridoma capable of producing an antibody that is capable of reacting specifically with a B cell stimulating factor-2 receptor protein that consists of the following amino acid sequence (I).",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US5480796A, Genentech Company: Actemra® Product"
                        },
                        {
                            "name": "Identified by Deposit  N",
                            "color": "teal",
                            "claimReason": "“…  a hybridoma identified by international deposit accession number FERM BP-6264 …”",
                            "indClaim": "<p>[IC]</p> 1. An antibody which specifically binds to osteoclastogenesis inhibitory factor binding molecule (OBM), wherein said antibody is antibody H-OBM 1, produced by a hybridoma identified by international deposit accession number FERM BP-6264.",
                            "depClaim": "<p>[DC]</p> 2. A hybridoma that produces the antibody of claim 1.<p>[DC]</p> 3. A composition comprising the antibody of claim 1 and one or more agents selected from the group consisting of a stabilizer, a pH adjuster, a buffering agent, a solubility agent and a detergent.",
                            "source": "<p>Source:</p> US7449185B2, Amgen Company: Xgeva® Product"
                        },
                        {
                            "name": "Glycoengineered",
                            "color": "teal",
                            "claimReason": "“… glycoengineered Chinese Hamster Ovary …”",
                            "indClaim": "<p>[IC]</p> 1. A glycoengineered Chinese Hamster Ovary cell that expresses a recombinant antibody comprising an IgG Fc region or fragment thereof containing N-linked oligosaccharides, wherein said Chinese Hamster Ovary cell has been genetically manipulated to have altered activity of at least one glycoprotein-modifying glycosyltransferase, wherein said antibody has an altered pattern of glycosylation in the Fc region compared to the corresponding antibody produced by the same Chinese Hamster Ovary cell that has not been glycoengineered, and wherein said antibody has increased Fc-mediated cellular cytotoxicity as a result of said altered glycosylation.",
                            "depClaim": "<p>[DC]</p> None.",
                            "source": "<p>Source:</p> US7906329B2, Roche Company: Gazyva® Product"
                        }
                    ]
                }
            ]
        },
        {
            "name": "Media",
            "color": "maroon",
            "children": [
                {
                    "name": "Cell Culture Medium",
                    "color": "maroon",
                    "claimReason": "“… ready-to-use glutamine-free cell culture medium containing asparagine for the production of a polypeptide in a production phase …”",
                    "indClaim": "<p>[IC]</p> 25. A ready-to-use glutamine-free cell culture medium containing asparagine for the production of a polypeptide in a production phase, wherein the asparagine is at a concentration in the range of 7.5 mM to 15 mM.",
                    "depClaim": "<p>[DC]</p> None.",
                    "source": "<p>Source:</p> US8512983B2, Genentech Company: Avastin® Product"
                }
            ]
        },
        {
            "name": "Sequence & Function",
            "color": "silver",
            "claimReason": "“... dissociates from human TNF with a Koff rate constant of 1×10-3 s-1 or less ...” & “... has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 ...”",
            "indClaim": "<p>[IC]</p> 9. An isolated human antibody, or antigen-binding portion thereof, with the following characteristics: <p>(a)</p> dissociates from human TNF with a Koff rate constant of 1×10-3 s-1 or less, as determined by surface plasmon resonance; <p>(b)</p> has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; <p>(c)</p> has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.",
            "depClaim": "<p>[DC]</p> 10. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human TNF with a Koff rate constant of 5×10-4 s-1 or less.<p>[DC]</p> 11. The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human TNF with a Koff rate constant of 1×10-4 s-1 or less.",
            "source": "<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
        }
    ]
}